Serum free light chain publications

From Wikilite

Jump to: navigation, search
Chapter

31

SECTION 6 - Appendices

Serum free light chain publications

Contents

1999

  1. Bradwell AR, Drew R, Showell PJ, Carr-Smith HD, Mead GP. Clinical potential of free immunoglobulin light-chain measurements. Clin Chem 1999; 45: 181a
  2. Tang LX, Showell PJ, Mead GP, Carr-Smith HD, Drew R, Bradwell AR. An automated nephelometric immunoassay for quantification of free light-chains in human serum and urine. Clinical Chemistry 1999; 45: 179a

2000

  1. Bradwell AR, Tang LX, Drayson MT, Drew RL. Immunoassays for detection of free light chains in sera of patients with nonsecretory myeloma. Blood 2000; 96: 4906a
  2. Carr Smith HD, Edwards J, Showell P, Drew R, Tang LX, Bradwell AR. Preparation of an immunoglobulin free light-chain reference material. Clin Chem 2000; 46: 699a
  3. Harris J, Tang LX, Showell PJ, Carr-Smith HD, Drew R, Bradwell AR. Assays for immunoglobulin free light chains in serum on the Beckman IMMAGE™. Clin Chem 2000; 46: A180a
  4. Tang LX, Showell P, Carr-Smith HD, Mead GP, Drew R, Bradwell AR. Evaluation of F(ab)2-based latex enhanced nephelometric reagents for free immunoglobulin light-chains on the Behring Nephelometer II. Clin Chem 2000; 46: 705a

2001

  1. Abraham RS, A. KJ, Clark RJ LJF, Dispenzieri A, Lust JA, Bradwell AR. Light chain myeloma: Correlation of serum nephelometric analysis for the quantitation of immunoglobulin free light chain with urine Bence Jones protein. Clin Chem 2001; 47: 108a
  2. Abraham RS, Bergen RH, Naylor S, Katzmann JA, Bradwell AR, Kyle RA, Fonseca R. Characterisation of free immunoglobulin light chains (LC) by mass spectroscopy in light chain-associated (AL) amyloidosis. Blood 2001; 98: 3772a
  3. Abraham RS, Katzmann JA, Clark RJ, Dispenzieri A, Lust JA, Bradwell AR, Kyle RA. Detection of serum immunoglobulin free light chains in primary amyloidosis and light chain deposition disease by nephelometry. Clin Chem 2001; 47: 107a
  4. Bradwell AR, Mead GP, Carr Smith HD, Drayson MT. Detection of Bence Jones myeloma and monitoring of myeloma chemotherapy using serum immunoassays specific for free immunoglobulin light chains. Blood 2001; 98: 633a
  5. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673 – 80 PMID: 11274017
  6. Bradwell AR, Drayson MT, Mead GP. Measurement of free light chains in urine (letter - reply). Clin Chem 2001; 47: 2069 – 70
  7. Bradwell AR, Smith L, Drayson MT, Mead GP, Carr Smith HD. Serum free light chain measurements for identifying and monitoring patients with nonsecretory myeloma. Clin Chem Lab Med 2001; 39: PO-F038a
  8. Bradwell AR, D. C-SH, L. S, P. MG. Detection and monitoring of nonsecretory myeloma using an assay for free light chains in serum. Clin Chem 2001; 47: 142a
  9. Carr-Smith HD, Smith L, Showell P, Mead GP, Drayson MT, Bradwell AR. Development of serum free immunoassays for the detection and monitoring of patients with Bence Jones myeloma. Hematol J 2001; 1: 70a
  10. Carr-Smith HD, Smith L, Showell P, Mead GP, Drayson MT, Bradwell AR. Detection and montioring of nonsecretory myeloma using assay for free light chains in serum. Hematol J 2001; 1: 71a
  11. Clark RJ, Katzmann JA, Abraham RS, Lymp JF, Kyle RA, Bradwell AR. Detection of monoclonal free light chains by nephelometry: Normal ranges and relative sensitivity. Clin Chem 2001; 47: 90a
  12. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900 – 2 Chem 2001; 47: 673 – 80 PMID: 11313287
  13. Graziani MS, Merlini G. Measurement of free light chains in urine. Clin Chem 2001; 47: 2069 - 70 PMID: 11673389
  14. Hansson L-O, Dijlai-Merzog R, Danielsson O, Bradwell AR. Quantitation of the free light chain kappa and lambda serum, urine and cerebrospinal fluid (CSF) using The Binding Site (F)ab2-based nephelometric method on the IMMAGE® system. Clin Chem 2001; 47: 106a
  15. Katzmann JA, Clarke RJ, Abraham RS, Lymp JF, Carr-Smith HD, Kyle RA, Bradwell AR. Detection of monoclonal free light chains in serum by nephelometry: Normal ranges and relative sensitivity. Proceedings of the Monoclonal Gammopathies & the Kidney 2001:OC1a
  16. Mead GP, Carr-Smith HD, Drayson MT, Hawkins PN, Bradwell AR. Serum free light chain immunoassays as an aid in the diagnosis and monitoring of light chain monoclonal gammopathies J Bone & Mineral Metab 2001; 19: 44a
  17. Smith L, Mead GP, Carr-Smith HD, Drayson MT, Bradwell AR. Detection and monitoring of Bence Jones myeloma using serum free light chain measurements. Clin Chem Lab Med 2001; 39: F039a
  18. Smith L, Mead GP, Carr-Smith HD, Drayson MT, Bradwell AR. Development of serum free light chain immunoassays for the detection and monitoring of patients with Bence Jones myeloma. Clin Chem 2001; 47: 141a


2002

  1. Abraham RS, Clark RJ, Bryant SC, Lymp JF, Larson T, Kyle RA, Katzmann JA. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 2002; 48: 655 – 7 PMID: 11901068
  2. Bradwell AR, Carr-Smith HD, Mead GP, Drayson MT. Serum free light chain immunoassays and their clinical application. Clin Appl Imm Rev 2002; 3: 17 – 33
  3. Bradwell AR, D. C-SH, P. MG, C. HT. Management of patients with light chain myeloma using serum free light chain immunoassays. Clin Chem 2002; 48: A51a
  4. Bradwell AR, Mead GP, Drayson MT, Carr-Smith HD. Serum immunoglobulin free light chain measurement in intact immunoglobulin myeloma. Blood 2002; 100: 5054a
  5. Bradwell AR, Drayson MT, Mead GP, Galvin G, Gasparetto C. Serum free light chain immunoassay for monitoring patients with light chain producing and nonsecretory myeloma. Blood 2002; 100: 5091a
  6. Carr-Smith HD, Showell P, Bradwell AR. Antigen excess assessment of free light chain assays on the Dade-Behring BNII nephelometer. Clin Chem 2002; 48: 23a
  7. Carr-Smith HD, Mead GP, Drayson MT, Hawkins PN, Bradwell AR. Detection and monitoring of light chain monoclonal gammopathies using serum free light chain immunoassays. Clin Chem Lab Med 2002; s: 42a
  8. Carr-Smith HD, Showell P, Bradwell AR. Development and evaluation of turbidemetric reagents for measuring free immunoglobulin light-chains on the Hitachi 911/ 912. Clin Chem Lab Med 2002; s: 43a
  9. Carr-Smith HD, Showell PJ, Matters DJ, Long JM, Bradwell AR. Development and evaluation of nephelometric reagents for measuring free immunoglobulin light-chains on a modified MininephTM. Clin Chem Lab Med 2002; s: 44a
  10. Hermsen D, Bradwell AR, Reinaauer H. Evaluation of an automated nephelometric immunoassay for quantification of free light chains in serum. J Lab Med 2002; 26: Q18a
  11. Hofmann W, Guder WG, Bradwell AR, Garbrecht M. Kappa and lambda light chain in serum and urine in patients with monoclonal gammopathy. J Lab Med 2002; 26: 19a
  12. Hofmann W, Guder WG, Bradwell AR, Garbrecht M. Detection of free kappa and lambda light chain in serum and urine in patients with monoclonal gammopathy. Onkologie: Int J Canc Res & Treatment 2002; 25: 752a
  13. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 1437 – 44 PMID: 12194920
  14. Lachmann HJ, Gallimore R, Gillmore JD, Smith L, Bradwell AR, Hawkins PN. Detection of monoclonal free light chains by nephelometry in systemic AL amyloidosis. Clin Chem 2002; 48: E45a
  15. Lachmann HJ, Gallimore R, Gillmore JD, Smith L, Bradwell AR, Hawkins PN. Correlation of changes in nephelometric quantification of serum monoclonal free light chains following chemotherapy and outcome in systemic AL amyloidosis. Clin Chem 2002; 48: E46a
  16. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Hawkins PN. Changes in the concentration of circulating free immunoglobulin chains and outcome in systemic AL Amyloidosis. Blood 2002; 100: 5090a
  17. Le Bricon T, Bengoufa D, Benlakehal M, Bousquet B, Erlich D. Urinary free light chain analysis by the Freelite immunoassay: a preliminary study in multiple myeloma. Clin Biochem 2002; 35: 565 – 7 PMID: 12493586
  18. Marien G, Bradwell AR, Blanckaert N, Bossuyt X. Detection of monoclonal proteins in sera by capillary zone electrophoresis and free ligh-chain measurments. Clin Chem 2002;48:E52a
  19. Marien G, Oris E, Bradwell AR, Blanckaert N, Bossuyt X. Detection of monoclonal proteins in sera by capillary zone electrophoresis and free light chain measurements. Clin Chem 2002; 48: 1600 – 1 PMID: 12194945
  20. Mead GP, Carr-Smith HD, Drayson MT, Bradwell AR. Detection of Bence Jones myeloma and monitoring of myeloma chemotherapy using immunoassays specific for free immunoglobulin light chains. Br J Haematol 2002; 117: 195a
  21. Mead GP, Stubbs PD, Carr-Smith HD, Drew R, Drayson MT, Bradwell AR. Nephelometric measurement of serum free light chains in nonsecretory myeloma. Clin Chem 2002; 48: 70a
  22. Showell PJ, Long JM, Carr-Smith HC, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Hitachi 911/912. Clin Chem 2002; 48: A66a
  23. Showell PJ, Matters DJ, Long JM, Carr-Smith HD, Bradwell AR. Evaluation of latex-enhanced nephelometric reagents for measuring free immunoglobulin light-chains on a modified Minineph™. Clin Chem 2002; 48: A67a
  24. Sirohi B, Powles R, Kulkarni S, Carr-Smith HD, Sankpal S, Patel G, et al. Serum free light chain assessment in myeloma patients who are in complete remission by immunofixation. Blood 2002; 100: 5095a
  25. Tate JR, Grimmett K, Mead GP, Cobcroft R, Gill D. Free light chain ratios in the serum of myeloma patients in complete remission following autologous peripheral blood stem cell transplantation. Clin Chem 2002; 48: E50a

2003

  1. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003; 119: 274 – 8 PMID: 12579999
  2. Alyanakian M-A, Abbas A, Delarue R, Arnulf B, Bradwell AR, Aucouturier P. Free immunoglobulin light chains serum levels in the follow-up of patients with monoclonal gammopathies: correlation with the 24H urinary light-chain excretion. Clin Chem 2003; 49: D54a
  3. Arneth B, Fischer C, Birklein F, Lackner KJ. The suitability of kappa free light chains in cerebrospinal fluid. Clin Chem Lab Med 2003; 41: 107a
  4. Bradwell AR. Clinical applications of serum free light chain immunoassays. Clin Lab Invest 2003; November
  5. Bradwell AR, Carr-Smith HD, Mead GP. Clinical utility of serum free light chain assays. Clin Chem Lab Med 2003; 41
  6. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489 – 91 PMID: 12583950
  7. Bradwell AR, Galvin GP, Mead GP, Carr-Smith HD. Practical use of serial measurements of serum free light chains to monitor response to treatment of multiple myeloma. Blood 2003; 102: 5234a
  8. Bradwell AR, Mead G, Carr-Smith H, Galvin G, Pratt G. Efficacy of high dose myeloma treatment and response to individual chemotherapy agents in myeloma is indicated by changes in serum free light chain concentrations. Blood 2003; 102: 2547a
  9. Bradwell AR, Mead GP, Drayson MT, Kyle RA, Katzmann JA. Role of serum free light chain measurements in disease diagnosis and monitoring. Hematol J 2003; 4
  10. Carr-Smith HD, Smith LJ, Bradwell AR. Serum free light chain assay development - specificity, sensitivity, standardisation and protocols. Clin Chem Lab Med 2003; 41: S72a
  11. Carr-Smith HD, Mead GP, Smith L, Drayson MT, Bradwell AR. Serum free light chain levels in patients with intact immunoglobulin myeloma. Br J Haematol 2003; 121: 198a
  12. Cohen AD, Zhou P, Xiao Q, Fleisher M, Kalakonda N, Akhurst T, et al. An unusual clinicopathologic association: Systemic AL amyloidosis due to Non-Hodgkin's Lymphoma. Blood 2003; 102: 4838a
  13. Graziani M, Merlini G, Petrini C. Guidelines for the analysis of Bence Jones protein. Clin Chem Lab Med 2003; 41: 338 – 46 12705344 PMID: 12705344
  14. Helmke KH, Oppermann MO, Teuber WT, Michels HM, Ventur YV, Welcker MW, Landenberg PL. Freie immunglobulin-leichtketten im serum bei rheumatischen erkrankungen. Z Rheumatol 2003; 62: Fr40a
  15. Hermsen D, Bradwell AR. Nephelometric detection of free kappa and lambda light chains in serum in patients with suspected monoclonal gammopathy. Onkologie 2003; 26: 697a
  16. Herzog W, Hofmann W. Detection of free kappa and lambda light chains in serum and urine in patients with monoclonal gammopathy. Blood 2003; 102: 5190a
  17. Hofmann W, Herzog W. Detection of free kappa and lambda light chain in serum and urine in patients with monoclonal gammopathy. Onkologie 2003; 26: 694a
  18. Hoffman U, Opperman M, Kuchler S, Ventur Y, Teuber W, Michels H, et al. Free immunoglobulin light chains in patients with rheumatic diseases. J Rheumatology 2003; 62: Fr40a
  19. Hunter HM, Peggs K, Powles R, Apperley J, Mahendra P, Canenagh J, et al. A comparison of outcome for patients undergoing non-myeloablative stem cell transplantation compared to conventional conditioning for multiple myeloma. Blood 2003; 102: 2705a
  20. Jaccard A, Moreau P, Aucouturier P, Ronco P, Fermand J-P, Hermine O. Amylose immunoglobulinique. Hématologie 2003; 9: 485 – 95
  21. Katzmann JA, Clark RJ, Rajkumar VS, Kyle RA. Monoclonal free light chains in sera from healthy individuals: FLC MGUS. Clin Chem 2003; 49: A74a
  22. Keren DF. Techniques to measure free kappa and free lambda light chains in serum and/or urine. Protein electrophoresis in clinical diagnosis, Arnold (Hodder Headline), 2003
  23. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122: 78 – 84 PMID: 12823348
  24. Martin W, Clark RJ, Shanafelt T, Katzmann JA, Bradwell AR, Abraham R, et al. Detection of serum free light chains in patients with B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Blood 2003; 102: 4827a
  25. Mead GP, Carr-Smith H, Drayson M, Bradwell AR. Serum free light chain concentrations and their use for disease monitoring in multiple myeloma patients with intact immunoglobulin monoclonal proteins. Hematol J 2003; 170
  26. Mead GP, Carr-Smith HD, Drayson MT, Bradwell AR. Elevated serum free light chain concentrations in multiple myeloma patients with intact immunoglobulin monoclonal proteins; their use for disease monitoring. Hematol J 2003; 4: 407a
  27. Mead GP, Carr-Smith HD, Drayson MT, Bradwell AR. Diagnosis and monitoring of multiple myeloma using serum free light chain concentrations. Onkologie 2003; 26: 695a
  28. Mead GP, Carr-Smith HD, Drayson MT, Bradwell AR. Serum free light chain assays provide improved monitoring of myeloma therapy. Br J Haematol 2003; 121: 205a
  29. Mead GP, Carr-Smith HD, Drayson MT, Bradwell AR. Serum free light chain levels in patients with intact immunoglobulin myeloma. Clin Chem 2003; 49: D61a
  30. Mead GP, Drayson MT, Carr-Smith HD, Bradwell AR. Measurement of immunoglobulin free light chains in serum. Clin Chem 2003; 49: 1957 – 8; author reply PMID: 14578337
  31. Mead GP, Pratt G, Bradwell AR. Frequent measurement of total immunoglobulin and serum free light chains in myeloma patients during peripheral blood stem cell transplantation. Hematol J 2003; 171
  32. Mead G, Bradwell AR, Lovell R, Pratt G. Changes in serum free light chain concentrations as a marker of disease response in myeloma patients after autologous stem cell transplantation. Onkologie 2003; 26
  33. Myers B, Lachmann H, Russell NH. Novel combination chemotherapy for primary (AL) amyloidosis myeloma: clinical, laboratory and serum amyloid-P protein scan improvement. Br J Haematol 2003; 121: 816 – 7 PMID: 12780799
  34. Myers B, Russell NH, McMillan AK. Use of a novel combination chemotherapy for AL-Amyloidosis: cyclophosphamide, thalidomide and dexamethasone - serum free light chain (SFLC) and serum amyloid protein P (SAP) scan results. Blood 2003; 102: 5249a
  35. Nowrousian MR, Brandhorst D, Daniels R, Sammet C, Schuett P, Ebeling P, et al. Free light-chain measurement in serum compared with immunofixation of urine in patients with multiple myeloma. Blood 2003; 102: 5197a
  36. Nowrousian MR, Brandhorst D, Daniels R, Sammet C, Schuett P, Ebeling P, Seeber S. Comparison between free light chain measurement in serum and immunofixation of urine in patients with multiple myeloma. Onkologie 2003; 26: 696a
  37. Ong S, Sethi S. Assessment of free light chain assasy in serum on the Beckman ImmageTM. Clin Chem 2003; 49: D59a.
  38. Overton J, Goodier D, Carr-Smith HD, Bradwell A. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Roche Modular P. Clin Chem 2003; 49: D60a
  39. Patten PE, Ahsan G, Kazmi M, Fields PA, Chick GW, Jones RR, et al. The early use of the serum free light chain assay in patients with relapsed refractory myeloma receiving treatment with thalidomide analogue (CC-4047). Blood 2003; 102: 1640a
  40. Rajkumar SV, Kyle RA, Therneau TM, Bradwell AR, Melton J, Katzmann JA. Presence of monoclonal free light chains in serum predicts risk of progression in monoclonal gammopathy of undetermined significance (MGUS). Blood 2003; 102: 3481a
  41. Reid SD, Mead GP, Drayson MT, Auguston B, Bradwell AR. Serum free light chains as sensitive marker of minimal residual disease in patients with multiple myeloma. Onkologie 2003;26
  42. Showell P, Matters D, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Olympus AU400. Proceedings of ACB National Meeting 2003: 13a
  43. Showell PJ, Matters DJ, Long JM, Carr-Smith HD, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Olympus AU400. Clin Chem 2003; 49: D55a
  44. Sirohi B, Powles R, Kulkarni S, Carr-Smith HD, Patel G, Das M, et al. Serum free light chain assessment in myeloma patients who are in complete remission (CR) by immunofixation predicts early relapse. Blood 2003; 102: 5195a
  45. Smith L, Showell P, Matters D, Carr-Smith HD, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Olympus AU400. Clin Chem Lab Med 2003: W497a
  46. Smith LJ, Long J, Matters DJ, Carr-Smith HD, Bradwell AR. Sample storage and stability for free light chain assays. Proceedings of ACB National Meeting 2003:2a
  47. Smith LJ, Long H, Matters DJ, Carr-Smith HD, Bradwell AR. Sample storage and stability for serum free light chain assays. Clin Chem 2003; 49: D57a
  48. Smith LJ, Long J, Carr-Smith HD, Bradwell AR. Measurement of immunoglobulin free light chains by automated homogeneous immunoassay in serum and plasma samples. Clin Chem 2003; 49: D58a
  49. Smith LJ, Mead GP, Bradwell AR. Comparative sensitivity of serum and urine assays for free light chains. Clin Chem Lab Med 2003; 41: S72a
  50. Tate JR, Gill D, Cobcroft R, Hickman PE. Practical considerations for the measurement of free light chains in serum. Clin Chem 2003; 49: 1252 – 7 PMID: 12881439
  51. Tate JR, Mollee P, Gill D. Measurement of Immunoglobulin Free Light Chains in Serum: Response. Clin Chem 2003; 49: 1958
  52. Terpos E, Politou M, Szydio R, Nadal E, Avery S, Olavarria E, et al. Autologous stem cell transplantation normalises abnormal bone resorption through the reduction of RANK/OPG ratio in multiple myeloma. Blood 2003; 102: 3658a
  53. Wands C, Powell M, Jupp R. The development of serum free light chain immunoassay on Bayer Advia. Proceedings of ACB National Meeting 2003; 2: 3a

2004

  1. Alyanakian MA, Abbas A, Delarue R, Arnulf B, Aucouturier P. Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion. Am J Hematol 2004; 75: 246 – 8 PMID: 15054820
  2. Augustson BM, Reid SD, Mead GP, Drayson MT, Child JA, Bradwell AR. Serum free light chain levels in asymptomatic myeloma. Blood 2004; 104: 4880a
  3. Berard A, Bouabdallah K. Chaines legeres libres: interet pour le diagnostic et le suivi des gammapathies monoclonales. Infos Biologiste Tribune 2004; 8: 12 – 3
  4. Bergen HR, 3rd, Abraham RS, Johnson KL, Bradwell AR, Naylor S. Characterization of amyloidogenic immunoglobulin light chains directly from serum by on-line immunoaffinity isolation. Biomed Chromatogr 2004; 18: 191 – 201 PMID: 15103706
  5. Bird JM, Cavenagh J, Samson D, Mehta A, Hawkins P, Lachmann H. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004; 125: 681 – 700 PMID: 15180858
  6. Bouabdallah K. Interet des chaines legeres libres dans la prise en charge des patients atteints de myelome. Biologiste infos 2004; 8: 12 – 3
  7. Bradwell AR, Garbincius J, Holmes EW. Serum free kappa to free lambda ratios as an adjunct to serum protein electrophoresis for the detection of monoclonal proteins in the serum. Blood 2004; 104: 4856a
  8. Carr-Smith HD, Harland B, Anderson J, Overton J, Wieringa G, Bradwell AR. The effect on laboratory organisation of introducing serum free light chain assays. Clin Chem 2004; 50: A76a
  9. Carr-Smith HD, Harland B, Anderson J, Overton J, Wieringa G, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light chains on the Bayer Advia 1650. Clin Chem 2004; 50: C44a
  10. Chou PP, Praither JD, Grainger A, Knight R. Serum free light chain assays. Clin Chem 2004; 50: C24a
  11. Cohen AD, Zhou P, Reich L, Quinn A, Fircanis S, Drake L, et al. Risk-adapted intravenous melphalan followed by adjuvant dexamethazone (D) and Thalidomide (T) for newly diagnosed patients with systemic AL amyloidosis (AL): Interim results of a phase II study. Blood 2004; 104: 542a
  12. Cohen AD, Zhou P, Xiao Q, Fleisher M, Kalakonda N, Akhurst T, et al. Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association. Br J Haematol 2004; 124: 309 – 14 PMID: 14717777
  13. Dispenzieri A, Gertz MA, Kyle RA. Response: Determining appropriate treatment options for patients with primary systemic amyloidosis. Blood 2004; 104: 2992 – 3
  14. Engelhardt M, Rapple D, Weis A, Bisse E, Thorst G. Serum free light chain (FLC) measurement in multiple myeloma (MM) patients (pts) correlate with known monoclonal paraprotein, disease stage and therapy response. Blood 2004; 104: 4907a
  15. Fischer CB, Arneth B, Koehler J, Lotz J, Lackner KJ. Kappa Free Light-chains in Cerebrospinal Fluid as Markers of Intrathecal Immunoglobulin Synthesis. Clin Chem 2004;50:1809-13 PMID: 15271859
  16. Fischer CB, Arneth B, Koehler J, Lackner K. The suitability of kappa free light chains in cerebrospinal fluid diagnostics. Clin Chem 2004; 50: B47a
  17. Gertz MA. Freelite immunoglobulin free light chain assay diagnostic: Serum test enables identification and monitoring of MM. Myeloma Today 2004; 6: 5 – 6
  18. Gertz M, Comenzo R, Falk RH, Fermand J-P, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in primary systemic amyloidosis (AL): A consensus opinion from the 10th International Symposium on amyloid and amyloidosis. Blood 2004; 104: 754a
  19. Gertz MA, Lacy MQ, Dispenzieri A. Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev 2004; 18: 17 – 37 PMID: 14684147
  20. Gertz MA, Merlini G, Treon SP. Amyloidosis and Waldenstrom's macroglobulinemia. Hematology Am Soc Hematol Educ Program 2004: 257 – 82 PMID: 15561687
  21. Goodman HJB, Lachmann HJ, Bradwell AR, Hawkins PN. Intermediate dose intravenous melphalan and dexamethasone treatment in 144 patients with systemic AL amyloidosis. Blood 2004; 104: 755a
  22. Guis L, Diemert MC, Ghillani P, Choquet S, Leblond V, Vernant JP, Musset L. The quantitation of serum free light chains: Three case reports. Clin Chem 2004; 50: F38a
  23. Hermsen D, Herzog W. Nephelometric detection of serum free kappa and lambda light chains in patients with suspected monoclonal free light chain gammopathies. Clin Chem 2004; 50: C19a
  24. Herzum I, Heinz R, Bruder-Burzlaff B, Renz H, Wahl HG. Reliability of the new freelite assay for quantification of free light chains in urine. Clin Chem 2004; 50: C36a
  25. Hofmann W, Garbrecht M, Bradwell AR, Guder WG. A new concept for detection of Bence Jones proteinuria in patients with monoclonal gammopathy. Clin Lab 2004; 50: 181 – 5 PMID: 15074473
  26. Katzmann JA, Dispenzieri A, Abraham R, Kyle R. Performance of free light chain assays in clinical practice Blood 2004;104:757a
  27. Mead GP, Bradwell AR, Lovell R, Pratt G. Changes in serum free light chain concentrations after high-dose melphalan and autologous stem cell transplant in myeloma patients. Bone Marrow Transplant 2004; 33: 380a.
  28. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126: 348 – 54 PMID: 15257706
  29. Mead GP, Carr-Smith HD, Galvin G, Pratt G, Bradwell AR. Efficacy of high dose treatment and response to individual chemotherapy agents in myeloma is indicated by changes in serum free light chain concentrations. Clin Chem 2004; 50: C20a
  30. Mead GP, Reid SD, Augustson BM, Drayson MT, Bradwell AR, Child JA. Correlation of serum free light chains and bone marrow plasma cell infiltration in multiple myeloma. Blood 2004; 104: 4865a
  31. Merlini G. Editorial: Sharpening therapeutic strategy in AL amyloidosis. Blood 2004; 104: 1593 – 4
  32. Merlini G, Palladini G, Bosoni T, Lavatelli F, D’Eril GM, Bradwell AR, Moratti R. Circulating free light chain concentration correlates with degree of cardiac dysfunction in AL amyloidosis. Clin Chem 2004; 50: B113a
  33. Nakano T, Nagata A, Takahashi H. Ratio of urinary free immunoglobulin light chain kappa to lambda in the diagnosis of Bence Jones proteinuria. Clin Chem Lab Med 2004; 42: 429 – 34 PMID: 15147154
  34. Pratt G, Mead G, Lovell R, Bradwell AR. Changes in serum-free light chain concentrtions as a marker of disease response in myeloma patients after autologous stem cell transplantation. Br J Haematol 2004; 125: 94a
  35. Rajkumar SV, Kyle RA, Therneau TM, Clark RJ, Bradwell AR, Melton LJ, 3rd, et al. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol 2004; 127: 308 – 10 PMID: 15491291
  36. Rajkumar SV, Kyle RA, Therneau TM, Melton LJI, Bradwell AR, Clark RJ, et al. Presence of an abnormal serum free light ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS). Blood 2004; 104: 3647a
  37. Räpple D, Weis A, Deschler B, Bisse E, Ihorst G, Englehardt M. Lambda (λ) - and kappa (κ) - free light chains in multiple myeloma (MM) patients correlate with known monoclonal paraprotein, disease stage and therapy response. Onkologie 2004; 27: 771a
  38. Reid SD, Drayson MT, Mead GP, Augustson B, Bradwell AR. Serum free light chains are a more sensitive marker of serological remission in multiple myeloma patients. Clin Chem 2004; 50: C34a
  39. Reid SD, Mead GP, Drayson MT, Bradwell AR. Comparison of immunofixation electrophoresis with serum free light chain measurement for determining complete remission in light chain multiple myeloma. Bone Marrow Transplant 2004; 33: 632a
  40. Sanchorawala V, Seldin DC, Wright DG, Skinner M, Finn KT, Falk RH. Pulsed low dose intravenous melphalan in patients with AL amyloidosis, ineligible for aggressive treatment with high-dose melphalan and stem cell transplantation. Blood 2004; 104: 2393a
  41. Sanchorawala V, Wright DG, Magnani B, Skinner M, Seldin DC. Serum free light chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) Amyloidosis. Blood 2004; 104: 942a
  42. Showell PJ, Lynch EA, Carr-Smith H, Bradwell AR. Evaluation of latex-enhanced nephelometric reagents for measuring free immunoglobulin light-chains on the Radim Delta. Clin Chem 2004; 50: C40a
  43. Sirohi B, Powles R, Kulkarni S, Carr Smith HD, Patel G, Das M, et al. Serum free light chain ratio is predictive of early relapse in patients who are in complete remission by immunofixation. Bone Marrow Transplant 2004;33: 649a
  44. Tate JR, Mollee P, Gill D. Serum free light chain ratios do not detect relapse in some patients with intact immunoglobulin myeloma post autologous peripheral blood stem cell transplantation. Clin Chem 2004; 50: B54a
  45. Thompson EJ. Editorial: Quality versus quantity: Which is better for cerebrospinal fluid IgG? Clin Chem 2004; 50: 1721 – 2
  46. Urban S, Oppermann M, Reucher SW, Schmolke M, Hoffmann U, Hiefinger-Schindlbeck R, Helmke KH. Free light chains (FLC) of immunoglobulins as parameter resembling disease activity in autoimmune rheumatic diseases. Ann Rheum Dis 2004; 63: 141a

2005

  1. Abdalla S, Goodman HJB, Hawkins PN. Thalidomide alone and in combination with other agents in the treatment of patients with AL amyloidosis. Haematologica 2005; 90: PO1411a
  2. Abdalla S. The use of serum free light chain assay in clinical practice. Haematologica 2005; 90: PO405a
  3. Akar H, Seldin DC, Magnani B, O'Hara C, Berk JL, Schoonmaker C, et al. Quantitative serum free light-chain assay in the diagnostic evaluation of AL amyloidosis. In: Grateau G, Kyle RA, Skinner M, eds. Amyloid and Amyloidosis, CRC Press, 2005
  4. Akar H, Seldin DC, Magnani B, O'Hara C, Berk JL, Schoonmaker C, et al. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. Amyloid 2005; 12: 210 – 5 PMID: 16399645
  5. Augustson BM, Katsavara H, Reid SD, Mead GP, Shirfield M, Bradwell AR. Monoclonal gammopathy screening: Improved sensitivity using the serum free light chain assay. Haematologica 2005; 90: PO1302a
  6. Augustson BM, Reid SD, Cohen D, Hawkins K, Mead G, Drayson M, et al. Normalisation of serum free light chains and negative immunofixation electrophoresis may be predictive of progression free survival and overall survival following high dose melphalan. Haematologica 2005; 90: PO403a
  7. Augustson BM, Reid SD, Mead GP, Drayson MT, Child JA, Bradwell AR. Serum free light chain levels in asymptomatic myeloma. Haematologica 2005; 90: PO1303a
  8. Bakshi NA, Gulbranson R, Garstka D, Bradwell AR, Keren DF. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M proteins. Am J Clin Pathol 2005; 124: 214 – 8 PMID: 16040291
  9. Beetham R, Howie N, Soutar R. Can opportunistic case-finding of paraproteins be clinically justified? Ann Clin Biochem 2005; 42: 245 – 53 PMID: 15989724
  10. Berard A. Quelques notions de rappel sur le myelome? Biologists Infos 2005; 15: 1 – 3
  11. Bergon E, Miravalles E, Miranda I, Bergon M. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma. Clin Chem Lab Med 2005; 43: 32 – 7 PMID: 15653439
  12. Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem 2005; 51: 805 – 7 PMID: 15855664
  13. Bradwell AR, Evans ND, Chappell MJ, Cockwell P, Reid SD, Harrison J, et al. Rapid removal of free light chains from serum by hemodialysis for patients with myeloma kidney. Blood 2005; 106: 3482a
  14. Bradwell AR, Mead GP, Chappell MJ, Evans ND. Model for assessing free light chain kinetics when monitoring patients with multiple myeloma. Haematologica 2005; 90: PO411a
  15. Brockhurst I, Harris KP, Chapman CS. Diagnosis and monitoring a case of light-chain deposition disease in the kidney using a new, sensitive immunoassay. Nephrol Dial Transplant 2005; 20: 1251 – 3 PMID: 15784642
  16. Carr-Smith HD, Abraham R, Mead GP, Goodman HJ, Hawkins PN, Bradwell AR. Measurement of serum free light chains in AL amyloidosis. In: Grateau G KR, Skinner M, ed. Amyloid and Amyloidosis, CRC Press, 2005: 154 – 6
  17. Carr-Smith HD, Mead GP, Bradwell AR. Serum free light chain assays as a replacement for urine electrophoresis. Haematologica 2005; 90: PO404a
  18. Cavallo F, Rasmussen E, Zangari M, Tricot G, Fender B, Fox M, et al. Serum free-lite chain (sFLC) assay in Multiple Myeloma (MM): Clinical correlates and prognostic implications in newly diagnosed MM patients treated with Total Therapy 2 or 3 (TT2/3). Blood 2005; 106: 3490a
  19. Chapuis-Cellier C, Foray V, Chazaud A, Troncy J. Contribution of the quantification of free light chains in 273 patients presenting with a newly discovered monoclonal gammopathy. Haematologica 2005; 90: PO408a
  20. Chapuis-Cellier C, Foray V, Chazaud A, Troncy J. Apparent discrepancies in the quantitation of free light chains in serum of patients presenting with a monoclonal gammopathy. Haematologica 2005; 90: PO409a
  21. Cohen AD, Zhou P, Reich L, Ford A, Hedvat C, Teruya-Feldstein J, et al. Interim analysis of a Phase II study of risk-adapted intravenous melphalan followed by adjuvant dexamethasone (D) and thalidomide (T) for newly diagnosed patients with systemic AL Amyloidosis (AL). Haematologica 2005; 90: PO1407a
  22. Comenzo RL. Light chains ahoy: Pirating Thal/Dex for AL too. Blood 2005; 105: 2625
  23. Comenzo RL, Zhou P, Reich L, Costello S, Quinn A, Fircanis S, et al. Risk-adapted intravenous melphalan with adjuvant Thalidomide and Dexamethazone for newly diagnosed untreated patients with systemic AL amyloidosis: interim report of a phase II trial. In: Grateau G, Kyle RA, Skinner M, eds. Amyloid and Amyloidosis, CRC Press, 2005: 112 – 5
  24. Comenzo RL, Zhou P, Reich L, Costello S, Quinn A, Fircanis S, et al. Prospective evaluation of the utility of the serum free light chain assay (FLC), Clonal Ig VLR gene identification and troponin 1 levels in a phase II trial of risk-adapted intravenous melphalan with adjuvant Thalidomide and Dexamethasone for newly diagnosed untreated patients with systemic AL amyloidosis. In: Grateau G, Kyle RA, Skinner M, eds. Amyloid and Amyloidosis, CRC Press, 2005: 167 – 9
  25. Comenzo RL, Zhou P, Wang L, Nimer SD, Olshen AB. Plasma cell gene-expression profiles in patients with systemic AL amyloidosis: Responses to melphalan and stem cell transplant are associated with differential expression of genes involved in translation, protein degradation and detoxification. Blood 2005; 106: 3405a
  26. Das M, Mead GP, Sreekanth V, Anderson J, Blair S, Howe T, et al. Serum free light chain (sFLC) concentration kinetics in patients receiving Bortezomib: Temporary inhibition of protein synthesis and early biomarker for disease response. Blood 2005; 106: 5094a
  27. Dellerba MP, James M, Butler SJ, Kelsey PR. Serum free light chain measurement in patients with multiple myeloma and Amyloidosis AL. Clin Chim Acta 2005;355: MP4.35a
  28. Desplat-Jego S, Feuillet L, Pelletier J, Bernard D, Cherif AA, Boucraut J. Quantification of immunoglobulin free light chains in cerebrospinal fluid by nephelometry. J Clin Immunol 2005; 25: 338 – 45 PMID: 16133990
  29. Dingli D, Kyle RA, Rajkumar VS, Nowakowski GS, Larson DR, Bida JP, et al. Immunoglobulin free light chains at diagnosis: Predictors of progression and survival in solitary plasmacytoma of bone. Blood 2005; 106: 5080a
  30. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, et al. Absolute values of serum immunoglobulin free light chains predict for survival in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplant. Blood 2005; 106: 422a
  31. Foray V, Chapuis-Cellier C. Contribution of serum free light chain immunoassays in diagnosis and monitoring of free light chain monoclonal gammopathies. Immuno-analyse et Biologie Spécialisée 2005; 20: 385 – 93
  32. Forsyth JM, Hill PG, Rai BS, Mayne S, Mead GP. Serum free light chain measurement can replace urine electrophoresis in the detection of B cell proliferative disorders. Blood 2005; 106: 5081a
  33. Forsyth JM, Hill PG, Rai BS, Mayne S, Mead GP. Serum free light chains in screening for B cell proliferative disorders. Clin Chim Acta 2005; 355: WP18.30a
  34. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in primary systemic amyloidosis (AL): A concensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Haematologica 2005; 90: PO1405a
  35. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319 – 28 PMID: 16044444
  36. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Ansell SM, et al. Role of second stem cell transplant in patients with amyloidosis who are refractory or relapsing. Blood 2005; 106: 5469a
  37. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis: diagnosis and management. Clin Lymphoma Myeloma 2005; 6: 208 – 19 PMID: 16354326
  38. Giarin MM, Di Bello C, Battaglio S, Falco P, Giaccone L, Boccadoro M. Serum free light chains: a new tool for diagnosis and management of multiple myeloma. Haematologica 2005; 90: 235a
  39. Gillmore JD, Wechalekar AD, Goodman HJB, Lachmann HJ, Offer M, Joshi J, Hawkins PN. Cardiac followed by autologous stem cell transplantation for systemic AL Amyloidosis. Blood 2005;106:1158a
  40. Goodman HJB, Wechalekar AD, Lachmann HJ, Bradwell AR, Hawkins PN. Clonal disease response and clinical outcome in 229 patients with AL amyloidosis treated with VAD-like chemotherapy. Haematologica 2005; 90: PO1408a
  41. Goodman HJ, Bridoux F, Lachmann HJ, Gilbertson JA, Gallimore R, Joshi J, et al. Localised amyloidosis: Clinical features and outcomes in 235 cases. Haematologica 2005; 90: PO1413a
  42. Gupta S, Comenzo RL, Hoffman BR, Fleisher M. National Academy of Clinical Biochemistry guidelines for the use of tumor markers in monoclonal gammopathies. http://www.aacc.org/sitecollectiondocuments/nacb/lmpg/tumor/chp3k_gammopathies.pdf
  43. Hammer F, Rolinski B, Scherberich JE. Impact of chronic renal failure on serum concentrations of free polyclonal immunoglobulin light chains. Nephro-News, Proceedings of Congress of Nephrology 2005; 10: 5a
  44. Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T, et al. The serum free light chain ratio after one or two cycles of treatment is highly predictive of the magnitude of final response in patients undergoing initial treatment for Multiple Myeloma. Blood 2005; 106: 972a
  45. Hazenberg BPC, Bijzet J, de Wit H, van Steijn J, Vellenga E, van Rijswijk MH. Diagnostic value of free kappa and lambda light chains in fat tissue of patients with systemic AL Amyloidosis. In: Grateau G, Kyle RA, Skinner M, eds. Amyloid and Amyloidosis, 2005: 107 – 8
  46. Henon KT, Dispenzieri A, Katzmann JA, Lacy MQ, Ramirez-Alvarado M, Gertz MA, et al. Circulating soluble light chain oligomers in sera of patients with light chain amyloidosis. Haematologica 2005; 90: PO1406a
  47. Herzog W, Mead GP, Reid SD, Hewins P, Cockwell P, Bradwell AR. The effect of renal impairment and dialysis on serum free light chain measurement. Nephro-News, Proceedings of Congress of Nephrology 2005: P8.03a
  48. Herzog W, Mead GP, Drayson MT, Bradwell AR. Serum free light chain immunoassays in the diagnosis of monoclonal Gammopathies. Nephro-News, Proceedings of Congress of Nephrology 2005: P12.04a
  49. Hill PG, Forsyth JM, Mayne S, Mead GP. Comparison of serum free light chain measurement and urine electrophoresis for detection of B cell proliferative disorders. Haematologica 2005; 90: PO406a
  50. Hill PG, Forsyth JM, Rai BS, Mayne S, Mead GP. Serum free light chain measurement can replace urine electrophoresis for detecting B cell proliferative disorders. Clin Chem 2005; 51: B6a
  51. Ihenetu KU, Abudu N, Miller J, Elin RJ. Free light chain assay shows greater clinical sensitivity than electrophoresis for detecting plasma cell dyscrasias. Clin Chem 2005; 51: B157a
  52. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776 – 83 PMID: 15953004
  53. Kang SY, Suh JT, Lee HJ, Yoon HJ, Lee WI. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. Ann Hematol 2005; 84: 588 – 93 PMID: 15883850
  54. Katsavara H, Reid SD, Augustson BM, Mead GP, Shirfield M, Drayson MT, et al. Screening for monoclonal gammopathy: Improved sensitivity using serum free light chain assays. Clin Chim Acta 2005; 355: TP4.06a
  55. Katzmann JA. Quantitative free light chain assays for the diagnosis and monitoring of monoclonal gammopathies. J Ligand Chem 2005; 27: 246 – 55
  56. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005; 51: 878 – 81 PMID: 15774572
  57. Katzmann JA, Dispenzieri A, Abraham RS, Lust JA, Kyle RA. Diagnostic Performance of Free Light Chain Assays in Clinical Practice. Clin Chem 2005; 51: D16a
  58. Keren D. Serum protein electrophoresis evaluation of monoclonal gammopathies (M-proteins). J Ligand Chem 2005; 27: 218 – 26
  59. Kühnemund A, Liebisch P, Bauchmüller K, Haas P, Kleber M, Bisse E, et al. Secondary light chain multiple myeloma with decreasing IgA paraprotein levels correlating with renal insufficiency and progressive disease: Clinical course of two patients and review of the literature. Onkologie 2005; 28
  60. Kumar S, Gertz MA, Hayman SR, Lacy MQ, Dispenzieri A, Zeldenrust SR, et al. Use of the serum free light chain assay in assessment of response to therapy in multiple myeloma: Validation of recently proposed response criteria in a prospective clinical trial of lenalidomide plus dexamethasone for newly diagnosed multiple myeloma. Blood 2005; 106: 3479a
  61. Kyrtsonis MC, Sachanas S, Vassilakopoulos TP, Kafassi N, Tzenou T, Papadogiannis A, et al. Bortezomib in patients with relapsed-refractory multiple myeloma (MM). Clinical observations. Blood 2005; 106: 5193a
  62. Leleu X, Moreau A-S, Coiteux V, Guieze R, Hennache B, Facon T, et al. Serum free light chain assays in solitary bone plasmacytoma. Clin Chim Acta 2005; 355: TP4.02a
  63. Leleu X, Moreau AS, Hennache B, Dupire S, Faucompret JL, Facon T, et al. Serum free light chain immunoassays measurement for monitoring solitary bone plasmacytoma. Haematologica 2005; 90: PO410a
  64. Leleu X, Moreau A-S, Coiteux V, Guieze R, Hennache B, Facon T, et al. Serum Free Light Chain Assays in Solitary Bone Plasmacytoma. Br J Haematol 2005; 129: 186a
  65. Lorenz EC, Gertz MA, Fervenza FC, Leung N. Long-term renal outcome of autologous stem cell transplantation in light chain deposition disease. Blood 2005; 106: 5518a
  66. Matsuda M, Yamada T, Gono T, Shimojima Y, Ishii W, Fushimi T, et al. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis. Intern Med 2005; 44: 428 – 33 PMID: 15942088
  67. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child AJ. Response to: Serum free light chains for monitoring multiple myeloma. Br J Haematol 2005; 128: 406 – 7
  68. Mead GP, Reid S, Augustson B, Drayson MT, Bradwell AR, Child JA. Comparison of serum and urine free light chain measurements with bone marrow assessments in multiple myeloma. Haematologica 2005; 90: PO407a
  69. Mead GP, Reid SD, Cockwell P, Hewins P, Bradwell AR. The effect of renal impairment and dialysis on serum free light chain measurement. . Haematologica 2005;90: PO237a
  70. Merkel S, Peest D, Witte T, Haller H, Schwarz A. Rekurrenz einer Leichtkettennephropathie im Transplantat - Therapiemöglichkeiten. Nephro-News, Proceedings of Congress of Nephrology 2005: P3.08a
  71. Mollee P, Tate J, Dimeski G, Gill D. Falsely low serum free light chain concentration in patients with monoclonal light chain diseases. Blood 2005; 106: 5077a
  72. Mösbauer U, Schieder H, Renges H, Ayuk F, Zander A, Kroger N. Serum free light chain [FLC] assay in multiple myeloma patients who achieved negative immunofixation after allogeneic stem cell transplantation. Blood 2005; 106: 2023a
  73. Munshi NC. Editorial: Determining the undetermined. Blood 2005; 106: 767 – 8
  74. Myers B. To the editor: Cardiac amyloidosis. Clin Med 2005; 5: 2 – 3
  75. Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005; 11: 8706 – 14 PMID: 16361557
  76. Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, et al. Relationship between serum concentrations and urinary excretions of monoclonal free light chains (mFLC) detectable as Bence Jones proteins (BJP) by immunofixation electrophoresis (IFE) in patients with multiple myeloma (MM). Blood 2005; 106: 5060a
  77. Offer M, Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Bradwell AR, Hawkins PN. Standard oral melphalan chemotherapy for AL amyloidosis revisited using the serum free light chain assay. Blood 2005; 106: 3495a
  78. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105: 2949 – 51 PMID: 15572585
  79. Palladini G, Perlini S, Vezzoli M, Perfetti V, Lavatelli F, Ferrero I, et al. The reduction of the serum concentration of the amyloidogenic light-chain in cardiac AL results in prompt improvement of myocardial function and prolonged survival despite unaltered amount of myocardial amyloid deposits. In: Grateau G, Kyle RA, Skinner M, eds. Amyloid and Amyloidosis, CRC Press, 2005: 73 – 5
  80. Peterson MR, Sumabat F, Nesbet L, Mullaney S, Smith D, Herold DA. Analysis of serum immunoglobulin free light chains in chronic hemodialysis patients. Am J Clin Path 2005; 124
  81. Pietrantuono A. Que sont les tests FreeliteTM. Bulletin des Syndicat National des Biologistes des Hopitaux 2005; 11
  82. Pratt G, Mead G, Bradwell A. Changes in serum free light chain concentrations as a marker of chemosensitivity after high-dose melphalan and autologous stem cell transplant in myeloma patients. Haematologica 2005;90: PO413a
  83. Rajkumar SV. MGUS and smoldering multiple myeloma: Update on pathogenesis, natural history and management. Hematology Am Soc Hematol Educ Program 2005: 340 – 5 PMID: 16304401
  84. Rajkumar SV, Kyle RA, Therneau TM, Melton JL, Bradwell AR, Clark RJ, et al. Abnormal serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS). Haematologica 2005; 90: PO1301a
  85. Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, 3rd, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812 – 7 PMID: 15855274
  86. Ramasamy I. Free immunoglobulin light chain serum levels in B cell dyscrasias. Clin Chem 2005; 51: B122a
  87. Reid SD, Augustson BM, Katsavara H, Drayson MT, Mead GP, Shirfield M, et al. Monoclonal gammopathy screening: Improved sensitivity using serum free light chain assays. Clin Chem 2005; 51: B20a
  88. Reid SD, Augustson BM, Katsavara H, Mead GP, Shirfield M, Drayson MT, et al. Screening for monoclonal gammopathy: Improved sensitivity using serum free light chain assays. Br J Haem 2005; 129: 81a
  89. Reid SD, Leleu X, Moreau AS, Coiteux V, Guieze R, Hennache B, et al. Serum free light chain assays in solitary bone plasmacytoma. Clin Chem 2005; 51: D13a
  90. Reid SD, Cockwell P, Hewins P, Millard JL, Mead GP, Bradwell AR. Haemodialysis removes free light chains from serum. Clin Chem 2005; 51: D12a
  91. Reid SD, Cockwell P, Hewins P, Mead GP, Bradwell AR. Efficient removal of serum free light chains by haemodialysis. Haematologica 2005; 90: PO512a
  92. Reid SD, Hewins P, Cockwell P, Millard JL, Mead GP, Bradwell AR. Haemodialysis removes free light chains from serum. Clin Chim Acta 2005; 355: MP10.5a
  93. Romeril KR, White G, Ritchie D. Thalidomide therapy in relapsed/refractory light chain myeloma. Haematologica 2005; 90: PO708a
  94. Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005; 36: 597 – 600 PMID: 16044137
  95. Sanchorawala V, Wright DG, Quillen K, Fisher C, Skinner M, Sedlin DC. Early serum free light chain responses following high-dose melphalan and stem cell transplantation for AL Amyloidosis predict treatment outcomes. Blood 2005; 106: 1160a
  96. Shimojima Y, Matsuda M, Gono T, Ishii W, Fushimi T, Hoshii Y, et al. Correlation between serum levels of free light chain and phenotype of plasma cells in bone marrow in primary AL amyloidosis. Amyloid 2005; 12: 33 – 40 PMID: 16076609
  97. Showell PJ, Lynch EA, Overton J, Carr-Smith HD, Bradwell AR. Evaluation of latex-enhanced nephelometric reagents for measuring free immunoglobulin light chains on the Dade Behring ProSpec. Clin Chem 2005; 51: B38a
  98. Smith DE, Abadie J, Bankson D, Mead G. Assessment of serum free light chain assay for screening for plasma cell disorders. Blood 2005; 106: 2563a
  99. Szarka C. Serum free light chain ratio predicts outcome in MGUS. Clin Lab Invest 2005; December
  100. Tate J, Mollee P, Gill D. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2005; 128: 405 - 6; author reply 406 – 407 PMID: 15667546
  101. Tate JR, Mollee P, Dimeski G, Gill D. Falsely low serum free light chain concentrations in patients with monoclonal light chain diseases. Clin Chem 2005; 51: B31a
  102. Tate JR, Mollee P, Gill D. Utility of serum free light chains for monitoring myeloma post autologous stem cell transplantation. Haematologica 2005; 90: PO412a
  103. van Steijn J, Bijzet J, de Wit H, Hazenberg BPC, van Gameren II, van de Belt K, Vellenga E. Serum levels of free kappa and lambda light chains in patients with systemic AL, AA and ATTR Amyloidosis. In: Grateau G, Kyle RA, Skinner M, eds. Amyloid and Amyloidosis, CRC Press, 2005: 105 – 6
  104. Walker R, Rasmussen E, Cavallo F, Jones-Jackson L, Anaissie E, Alpe T, et al. Correlation of suppression of FDG PET uptake with serum free light chain levels - both FDG PET-CT and serum clonal free light chain response precede and predict the likelihood of subsequent complete remission in newly diagnosed multiple myeloma. Blood 2005; 106: 3493a
  105. Walker SA, Roddie PH, Ashby JP. Evaluation of serum free light chain (FLC) measurements as an alternative to urine Bence Jones (BJP) analysis in a routine laboratory setting. Clin Chim Acta 2005; 355: WP18.32a
  106. Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Offer M, Bradwell AR, Hawkins PN. Clinical profile and treatment outcome in 92 Patients with AL amyloidosis associated with IgM paraproteinaemia. Blood 2005; 106: 3498a
  107. Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Offer M, Bradwell AR, Hawkins PN. Efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis. Blood 2005; 106: 3496a
  108. Wechalekar AD, Lachmann HJ, Goodman HJB, Bradwell AR, Hawkins PN. Role of serum free light chains in diagnosis and monitoring response to treatment in light chain deposition disease. Haematologica 2005; 90: PO1414a
  109. Yagmur E, Mertens PR, Gressner AM, Kiefer P. Free light chain kappa/lambda ratios are also of diagnotic value for patients with renal insufficiency Nephro-News, Proceedings of Congress of Nephrology 2005; 102: P12.04a

2006

  1. Abadie JM, Bankson DD. Assessment of Serum Free Light Chain Assays for Plasma Cell Disorder Screening in a Veterans Affairs Population. Ann Clin Lab Sci 2006; 36: 157 - 62 PMID: 16682511
  2. Blade J. Clinical practice. Monoclonal gammopathy of undetermined significance. N Engl J Med 2006;355: 2765 – 70 PMID: 17192542
  3. Bradwell AR, Harding SJ. Paraprotein management: Response to Smellie WSA, Spickett GP: BMJ 2006; 333: 185 - 187. BMJ, 7th August 2006
  4. Campbell P, Murdock C. Cardiac amyloidosis--sustained clinical and free light chain response to low dose thalidomide and corticosteroids. Intern Med J 2006; 36: 137 – 9 PMID: 16472271
  5. Catarini M, Pieroni S, Monachesi A. Serum free light chains: A potential marker for diagnosis, early assessment of response to treatment and relapse in plasma cell disorders. Haematologica 2006; 91: PO153a
  6. Chang-Ki M, Ki-Seong E, Seok L, Jong-Wook L, Woo-Sung M, Chong-Won P, et al. Changes in serum free light chain and biochemical markers in patients with multiple myeloma receiving bortezomib treatment. Blood 2006; 108: 5028a
  7. Comenzo RL. Amyloidosis. Curr Treat Options Oncol 2006; 7: 225 – 36 PMID: 16615878
  8. Dingli D, Kyle RA, Rajkumar SV, Nowakowski GS, Larson DR, Bida JP, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006; 108: 1979 – 83 PMID: 16741249
  9. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006; 107: 3378 – 83 PMID: 16397135
  10. Dispenzieri A, Rajkumar SV, Plevak MF, Katzmann JA, Kyle RA, Larson D, et al. Early immunoglobulin free light chain (FLC) response post autologous peripheral blood stem cell transplant predicts for hematologic complete response in patients with multiple myeloma. Blood 2006; 108: 3097a
  11. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467 – 73 PMID: 16855634
  12. Franke DD, Gousha N, Levinson SS. Analysis of immunoglobulin free light chains in Urine: A sensitive assay to characterize Bence Jones proteinuria. Clin Chem 2006; 52: E9a
  13. Friedman JF, Al-Zoubi A, Kaminski M, Kendall T, Jakubowiak A. A new model predicting at least a very good partial response in patients with multiple myeloma (MM) after 2 cycles of bortezomib-based therapy. Haematologica 2006; 91: PO741a
  14. Gertz MA. Monitoring organ response in amyloidosis. Blood 2006; 107: 3814a
  15. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Gastineau DA. Extent of hematologic response is important in determining outcome in transplanted patients with primary amyloidosis AL. Importance of achieving CR. Blood 2006; 108: 611a
  16. Giarin MM, Giaccone L, Bruno B, Omedè P, Battaglio S, Falco P, et al. Serum free light chains: a potential useful marker for diagnosis and early assessment of response to treatment and relapse in plasma cell disorders. Haematologica Reports 2006; 2: 4a
  17. Giarin MM, Giaccone L, Caracciolo D, Bruno B, Falco P, Omedè P, et al. Serum free light chains (SFLC) assay: a suggestive new criteria for evaluating disease response, progression and relapse in plasma-cell disorders (PD) and a prognostic factor in monoclonal gammopathy of undetermined significance (MGUS). Haematologica 2006; 91: PO151a
  18. Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J, et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006; 107: 1227 – 9 PMID: 16210334
  19. Goodman HJ, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006; 134: 417 – 25 PMID: 16822290
  20. Hajdu SI. A note from history: the first biochemical test for detection of cancer. Ann Clin Lab Sci 2006; 36: 222 – 3 PMID: 16682523
  21. Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T, et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol 2006; 132: 155 – 61 PMID: 16398649
  22. Hill PG, Forsyth JM, Rai B, Mayne S. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem 2006; 52: 1743 – 8 PMID: 16858075
  23. Hutchison C, Bradwell AR, Mead G, Chandler K, Harper J, Cook M, et al. Free light chain removal by extended hemodialysis in patients with cast nephropathy from multiple myeloma. J Am Soc Nephrol 2006; 17: TH-FC102a
  24. Hutchison C, Chandler K, Mead G, Cockwell P, Bradwell AR. Free light chain removal from serum by haemofiltration and haemodialysis: a comparison of dialysis membranes in vitro. J Am Soc Nephrol 2006; 17: PUB237a
  25. Hutchison C, Cockwell P, Chandler K, Harper J, Mead G, Barnett AH, Bradwell AR. Light chain abnormalities in diabetic patients with and without microalbuminuria. J Am Soc Nephrol 2006; 17: TH-PO231a
  26. Hutchison C, Cockwell P, Chandler K, Harper J, Mead G, Barnett AH, Bradwell AR. Light chain abnormalities in diabetic patients with and without microalbuminuria. J Am Soc Nephrol 2006; 17: TH-PO231a
  27. Hutchison C, Cockwell P, Hatersley J, Evans N, Chappell MJ, Mead G, Bradwell A. Simulations of free light chain removal by extended haemodialysis using a mathematical model. J Am Soc Nephrol 2006; 17: PUB238a
  28. Hutchison C, Cockwell P, Reid C, Chandler K, Mead GP, Harrison J, et al. Efficient removal of immunoglobulin free light chains by hemodialysis in multiple myeloma: In-vitro and in-vivo studies. Blood 2006; 108: 5112a
  29. Hutchison CA, Cockwell P, Reid SD, Chandler KL, Millard JL, Mead GP, et al. Removal of serum free light chains by hemodialysis in patients with multiple myeloma. Clin Chem 2006; 52: A81a
  30. Hutchison C, Cook M, Bradwell AR, Cockwell P. Renal recovery following light chain removal by extended haemodialysis in a patient with cast nephropathy. Blood 2006; 108: 5115a
  31. Hutchison C, Cook M, Bradwell AR, Cockwell P. Renal recovery following light chain removal by extended hemodialysis in a patient with cast nephropathy from multiple myeloma. J Am Soc Nephrol 2006; 17: TH-PO268a
  32. Hutchison CA, Mead G, Chandler K, Harper J, Bradwell AR, Cockwell P. Free light chain abnormalities in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: PUB393a
  33. Hutchison CA, Mead G, Harper J, Chandler K, Bradwell AR, Cockwell P. Free light chain abnormalities in patients with renal transplants. J Am Soc Nephrol 2006; 17: TH-PO060a
  34. Hutchison CA, Townend J, Mead G, Chandler K, Harper J, Bradwell AR, et al. Serum free light chains as a determinant of adverse outcomes in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: PUB391a
  35. Hutchison C, Townend J, Mead GP, Chandler K, Harper J, Bradwell AR, et al. Monoclonal gammopathy as a determinant of adverse outcomes in patients with chronic kidney disease. Blood 2006; 108: 5053a
  36. Itzykson R, Garff-Tavernier M, Katsahian S, Diemert M-C, Guis L, Choquet S, et al. Serum free light chain (SFLC) elevation Is associated with high 2-microglobulin and with a shorter time to treatment in Waldenstrom's Macroglobulinemia (WM). Blood 2006; 108: 2419a
  37. Jaskowski TD, Litwin CM, Hill HR. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis. Clin Vaccine Immunol 2006; 13: 277 – 80 PMID: 12881439
  38. Katzmann JA. Serum free light chain specificity and sensitivity: a reality check. Clin Chem 2006; 52: 1638 – 9 PMID: 16940461
  39. Katzmann JA. Serum free light chains - quantitation and clinical utility in assessing monoclonal gammopathies. Clinical Lab News 2006; June: 12 – 4
  40. Katzmann JA, Dispenzieri A, Kyle RA, Snyder MR, Plevak MF, Larson DR, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006; 81: 1575 – 8 PMID: 17165636
  41. Katzmann JA, Dispenzieri A, Kyle RA, Snyder MR, Plevak MF, Larson DR, et al. Elimination of the need for urine studies during diagnostic studies of monoclonal gammopathies by the combined use of serum immunofixation and serum free light chain assays. Blood 2006; 108: 5011a
  42. Kumar S, Fonseca R, Dispenzieri A, Katzmann JA, Kyle RA, Clark R, Rajkumar SV. High incidence of IgH translocations in monoclonal gammopathies with abnormal free light chain levels. Blood 2006; 108: 3514a
  43. Kumar S, Rajkumar VS, Plevak M, Kyle RA, Katzmann JA, Dispenzieri A. Comparison of serum free light chain levels and 24 hour urinary monoclonal protein secretion in patients with myeloma: Concordant changes with response to therapy. Blood 2006; 108: 5064a
  44. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134: 573 – 89 PMID: 16938117
  45. Kyrtsonis M-C, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A, et al. Serum free light chain ratio (FLCR) at diagnosis constitute a powerful prognostic factor of survival in multiple myeloma (MM). Blood 2006; 108: 3522a
  46. Lopez J, Dauwalder O, Joly P, Dimet I, Bienvenu J, Bernon H. [Interest and limit of a free light chain immunoassay in serum and urine for the diagnosis and the follow-up of monoclonal dysglobulinemia]. Ann Biol Clin (Paris) 2006; 64: 287 – 97 PMID: 16698567
  47. Lueck N, Agrawal YP. Lack of utility of free light chain-specific antibodies in the urine immunofixation test. Clin Chem 2006; 52: 906 – 7 PMID: 16361557
  48. Mazumder A, Jagannath S. Use of free light chain measurements in clinical trials of novel agents in multiple myeloma. Blood 2006; 108: 3584a
  49. Mead G, Beardsmore C, Reid S, Hattersley J, Moss P, Pratt G, et al. Kinetics of tumour kill during induction chemotherapy for multiple myeloma using frequent free light chain measurements. Haematologica 2006; 92: PO1219a
  50. Mehta AB. Practice: Paraprotein management. Reply to Smellie WSA, Spickett GP. BMJ 2006; 333: 185 – 7
  51. Mehta J, Stein R, Vickrey E, Resseguie W, Singhal S. Significance of serum free light chain estimation with detectable serum monoclonal protein on immunofixation electrophoresis. Blood 2006; 108: 5048a
  52. Min C-K, Eom K-S, Lee S, Lee J-W, Min W-S, Park C-W, et al. Changes in serum free light chain and biochemical markers in patients with multiple myeloma receiving bortezomib treatment. Blood 2006; 108: 5028a
  53. Moreau A-S, Leleu X, Manning R, Coiteux V, Darre S, Hatjiharisi E, et al. Serum free light chains in Waldenstrom Macroglobulinemia. Blood 2006; 108: 2420a
  54. Nakano T, Miyazaki S, Shinoda Y, Inoue I, Katayama S, Komoda T, Nagata A. Proposed reference material for human free immunoglobulin light chain measurement. J Immunoassay Immunochem 2006; 27: 129 – 37 PMID: 16711251
  55. Nakano T, Miyazaki S, Takahashi H, Matsumori A, Maruyama T, Komoda T, Nagata A. Immunochemical quantification of free immunoglobulin light chains from an analytical perspective. Clin Chem Lab Med 2006; 44: 522 – 32 PMID: 16681419.
  56. Offidani M, Polloni C, Corvatta L, Marconi M, Piersantelli MN, Scortechini I, et al. Usefulness of serum free light chain assay (sFLC) in predicting response to chemotherapy in patients affected by multiple myeloma. Haematologica Reports 2006; 2: 7a.
  57. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006; 107: 3854 – 8 PMID: 16434487
  58. Palladini G, Russo P, Lavatelli F, Nuvolone M, Bosoni T, D'Eril GM, et al. Diagnostic performance of the quantitative assay for free light chains (Freelite™) in AL amyloidosis. Clin Chem 2006; 52: D123a
  59. Palladini G, Perfetti V, Merlini G. Therapy and management of systemic AL (primary) amyloidosis. Swiss Med Wkly 2006; 136: 715 – 20 PMID: 17183435
  60. Polloni C, Offidani M, Corvatta L, Marconi M, Piersantelli MN, Amoroso B, Leoni P. Role of serum free light chain (sFLC) level and ratio (FLCr) as early predictors of response in multiple myeloma. Haematologica 2006; 91: PO152a
  61. Pratt G, Mead GP, Godfrey KR, Hu Y, Evans ND, Chappell MJ, et al. The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains. Leuk Lymphoma 2006; 47: 21 – 8 PMID: 16321823
  62. Presslauer S, Milosavljevic D, Hubl W, Brucke T, Bayer P. Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. Multiple Sclerosis 2006; 12: 783a
  63. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006; 81: 693 – 703 PMID: 16706268
  64. Rajkumar SV, Kyle RA, Plevak M, Clark RJ, Larson D, Therneau T, et al. Prevalance of light-chain monoclonal gammopathy of undetermined significance (LC-MGUS) among Olmsted Country, Minnesota residents aged 50 years of greater. Blood 2006; 108: 5060a
  65. Reid SD, Cockwell P, Millard JL, Chandler KL, Hutchison CA, Mead GP, Bradwell AR. MGUS incidence in a chronic kidney disease population. Clin Chem 2006; 52: E38a
  66. Reid SD, Katsavara H, Augustson BM, Hutchison CA, Mead GP, Shirfield M, et al. Screening for monoclonal gammopathy: inclusion of serum free light chain immunoassays produce an increased detection rate. Clin Chem 2006; 52: E37a
  67. Reid S, Chandler K, Hutchison C, Harrison J, Cockwell P, Mead G, Bradwell A. Free light chain removal from serum by haemofiltration and haemodialysis: a comparison of dialysis membranes in vitro. Nephrol Dial Transplant 2006; 21: SP676a
  68. Reid S, Cockwell P, Chandler K, Hutchison CA, Mead G, Bradwell AR. MGUS incidence in a chronic kidney disease population. Nephrol Dial Transplant 2006; 21: MP287a
  69. Rinker JR, 2nd, Trinkaus K, Cross AH. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology 2006; 67: 1288 – 90 18685917 PMID: 18685917
  70. Rolinski B, Hammer F, Scherberich J. Clearance of kappa and lambda free light chains during hemodialysis. Clin Chem Lab Med 2006; 44: 117a
  71. Rolinski B, Hammer F, Scherberich JE. Serum concentrations of kappa and lambda free light chains in chronic renal failure. Clin Chem Lab Med 2006; 44: 118a
  72. Rutherford C, Wians FH. A large skull mass in a 67 year-old woman. Lab Med 2006; 37: 417 – 21
  73. Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol 2006;1:1331-41 PMID: 17699366
  74. Scherberich J, Hammer F, Rolinski B. Impact of chronic renal failure and hameodialysis on serum free polyclonal immunoglobulin kapp/lambda light-chains. Nephrology Dialysis Transplantation 2006; 21: SP021a
  75. Shaw GR. Nonsecretory plasma cell myeloma--becoming even more rare with serum free light-chain assay: a brief review. Arch Pathol Lab Med 2006; 130: 1212 - 5 PMID: 16879026
  76. Shimizu K, Itoh J, Sugiura I, Tsushita K, Kosugi H, Nagura E. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma]. Rinsho Ketsueki 2006; 47: 303 – 9 PMID: 16715965
  77. Showell PJ, Scurvin M, Chnivimba A, Carr-Smith HC, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on The Binding Site automated analyser. Clin Chem 2006; 52: E41a
  78. Singhal S, Stein R, Vickrey E, Resseguie W, Mehta J. The serum free light chain assay cannot replace 24-hour urine protein estimation in plasma cell dyscrasias. Blood 2006; 108: 3516a
  79. Smellie WSA. Practice: Paraprotein management. Reply to Mehta AB. BMJ 2006; 333: 185 – 7
  80. Smellie WS, Spickett GP. Paraprotein management. BMJ 2006; 333: 185 – 7
  81. Smellie WSA, Spickett GP. Practice: Paraprotein management. Reply to Bradwell AR and Harding SJ. BMJ 2006; 333: 185 – 6
  82. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006; 132: 410 – 51 PMID: 16412016
  83. Stein R, Mehta J, Vickrey E, Resseguie W, Singhal S. Serum free light chain measurement in myeloma patient samples with oligoclonal protein bands. Blood 2006; 108: 5044a
  84. Stein R, Mehta J, Vickrey E, Resseguie W, Singhal S. Correlation of serum free light chain levels with other parameters in myeloma. Blood 2006; 108: 5019a
  85. Tate JR, Mollee P, Carter A, Gill D. Clinical utility and technical pitfalls of the serum free light (FLC) assay for monitoring of monoclonal light-chain diseases. Clin Chem 2006; 52: E44a
  86. Tucker KF. Computer program for monitoring disease status in multiple myeloma with serum free kappa, and free lambda chains. Clin Chem 2006; 52: D137a
  87. Van der Heijden M, Kraneveld A, Redegeld F. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur J Pharmacol 2006; 533: 319 – 26 PMID: 16455071
  88. Van Gysel M, Marien G, Verhoef G, Delforge M, Bossuyt X. Free light chain testing in follow-up of multiple myeloma. Clin Chem Lab Med 2006; 44: 1044 – 6 PMID: 16879076
  89. Wechalekar AD, Gillmore JD, Lachmann HJ, Offer M, Hawkins PN. Efficacy and safety of bortezomib in systemic AL amyloidosis - a preliminary report. Blood 2006; 108: 129a

2007

  1. Abdalla SH. Use of Freelite assay to monitor myeloma with renal failure. Haematologica 2007; 92: PO1016a
  2. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, et al. Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007; 5: 118 – 47 PMID: 17335683
  3. Ayliffe MJ, Davies FE, de Castro D, Morgan GJ. Demonstration of changes in plasma cell subsets in multiple myeloma. Haematologica 2007; 92: 1135 – 8 PMID: 17650446
  4. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176 – 85 PMID: 17593024
  5. Basu S, Cook M, Hutchison C, Galvin GP, Harding S, Mead G, et al. High rate of renal recovery in patients with cast nephropathy treated by removal of free light chains using extended hemodialysis. Haematologica 2007; 92: PO1109a
  6. Beetham R, Wassell J, Wallage MJ, Whiteway AJ, James JA. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies? Ann Clin Biochem 2007; 44: 516 – 22 PMID: 17961305
  7. Behrens J. Fighting fit. Med Lab World 2007;August:7
  8. Bergner R, Hoffmann M, Landmann T, Uppenkamp M. Free light chains in urine - an additional diagnostic advantage? Haematologica 2007; 92: PO1012a
  9. Bradwell AR, Cockwell P, Hutchison CA. Removal of nephrotoxic free light chains by haemodialysis in patients with myeloma kidney. NHS Nat Library for Health 2007
  10. Clark RJ, Lockington KS, Tostrud LJ, Katzmann JA. Incidence of antigen excess in serum free light chain assays. Clin Chem 2007; 53: C145a
  11. Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 2007; 139: 224 – 33 PMID: 17897298
  12. Comenzo RL. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis. Contrib Nephrol 2007; 153: 195 – 210 PMID: 17075231
  13. Comenzo RL. Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw 2007; 5: 179 – 87 PMID: 17335687
  14. Comenzo RL, Maurer M, Cohen A, Hassoun H, Zhou P, Lu P, et al. Predictors of survival in de novo cardiac Amyloidosis. Blood 2007; 110: 2870a
  15. Cook M, Hutchison C, Basu S, Harding S, Basnayake K, Mead G, et al. Renal recovery in 75% of myeloma patients with cast nephropathy following FLC removal by hemodialysis. Haematologica 2007; 92: PO1106a
  16. Corso A, Barbarano L, Mangiacavalli S, Montalbetti L, Brasca P, Zappasodi P, et al. Bortezomib with HIG-dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high-dose therapy. Blood 2007; 110: 3595a
  17. Cserti C, Haspel R, Stowell C, Dzik W. Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion 2007; 47: 511 – 4 PMID: 17319833
  18. Daval S, Tridon A, Mazeron N, Ristori JM, Evrard B. Risk of antigen excess in serum free light chain measurements. Clin Chem 2007; 53: 1985 – 6 PMID: 17954504
  19. Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007; 92: 143 – 4 PMID: 17229655
  20. De Souza CA, Oliveira-Duarte G, Dias DF, Bottini PV, Vigorito AC, Aranha FJP, et al. Serum free light-chain measurements for monitoring minimal residual disease after stem cell transplantation in multiple myeloma patients. Haematologica 2007; 92: PO1181a
  21. Dingli D, Pacheco JM, Dispenzieri A, Hayman SR, Kumar SK, Lacy MQ, et al. Serum M-spike and transplant outcome in patients with multiple myeloma. Cancer Sci 2007; 98: 1035 – 40 PMID: 17488336
  22. Dispenzieri A, Kyle RA, Katzmann JA, Larson D, Benson J, Clark RJ, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering multiple myeloma. Blood 2007; 110: 1487a
  23. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007; 109: 465 – 70 PMID: 17008538
  24. Dispenzieri A, Zhang L, Snyder M, Blood E, Katzmann JA, DeGoey R, et al. FLC as a marker of response in a mature dataset: EC0G E9486. Haematologica 2007; 92: PO1013a
  25. Émond JP, Harding S, Lemieux B. Aggregation of serum free light chains (FLC) causes overestimation of FLC nephelometric results as compared to serum protein electrophoresis (SPE) while preserving clinical usefulness. Blood 2007; 110: 4767a
  26. Émond JP, Lemieux B, Biron G. Two algorithms for screening or follow up of monoclonal gammopathies: advantages and pitfalls of serum free light chains. Clin Chem Lab Med 2007; 45: M057a
  27. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S. Transplantation for amyloidosis. Current opinion in oncology 2007; 19: 136 – 41 PMID: 17272986
  28. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Leung N, Gastineau DA. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007; 92: 1415 – 8 PMID: 17768110
  29. Gironella M. Free-light chain contribution to the evaluation of response after stem-cell transplantation in multiple myeloma. Haematologica 2007; 92: 1312a
  30. Gottenberg JE, Aucouturier F, Goetz J, Sordet C, Jahn I, Busson M, et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 2007; 66: 23 – 7 PMID: 16569685
  31. Grosbois B. [New insights into monoclonal gammopathy and multiple myeloma]. Rev Med Interne 2007; 28: 667 – 9 PMID: 17553600
  32. Guenet L, Decaux O, Lechartier H, Ropert M, Grosbois B. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy]. Rev Med Interne 2007; 28: 689 – 97 PMID: 17566612
  33. Hajek R, Hajek R, Cermakova Z, Pour L, Novotna H, Maisnar V, et al. Free light chain assays for early detection of resistance to bortezomib-based regimens. Haematologica 2007; 92: 257a
  34. Harding S, Drayson M, Ayliffe M, Mead G. Flow cytometry detection of free light chains. Haematologica 2007; 92: PO205a
  35. Harding S, Mead G, McSkeane T, Beardsmore C, Hatterskey SJ, Moss P, et al. Use of free light chain measurements as prediction of response to induction chemotherapy. Br J Haematol 2007; 137: 134a
  36. Harousseau JL. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18 ii44 – 6 PMID: 17491042
  37. Hassoun H, Rafferty BT, Flombaum C, D'Agati VD, Klimek VM, Cohen A, et al. High dose chemotherapy and autologous stem cell transplantation with melphalan in patients with monoclonal immunoglobulin deposition disease associated with Multiple Myeloma. Blood 2007; 110: 5113a
  38. Herrera GA, Sanders PW. Paraproteinemic Renal Diseases that Involve the Tubulo-Interstitium. Contrib Nephrol 2007;153: 105 – 15 PMID: 17075226
  39. Herrera GA. The kidney in plasma cell dyscrasias: a current view and a look at the future. Contrib Nephrol 2007; 153: 1 – 4 PMID: 17075220
  40. Higgins C. Science Review: Multiple myeloma and serum free light chain measurement. The Biomedical Scientist 2007; 51: 428 – 31
  41. Higgins T, Cho C, Dayton J. Evaluation of a method to measure free light chains using Bayer Advia 1650 chemistry analyzer. Clin Chem Lab Med 2007; 45: M316a
  42. Hildebrandt B, Muller C, Pezzutto A, Daniel P, Dorken B, Scholz C. Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis - a pilot study. BMC Cancer 2007; 7: 185 17915026 PMID: 17915026
  43. Holding S, Spradbery D, Hoole R, Wilmot R, Shields ML, Patmore R, Dore PC. Prevalence of abnormal serum free light chain ratio in monoclonal gammopathies at presentation and sensitivity for Bence Jones proteinuria. Blood 2007; 110: 1495a
  44. Holding S, Spradbery D, Robson EJD, Dore PC, Wilmot R, Shields ML. Combination of serum free light chain analysis with capillary zone electrophoresis improves screening for monoclonal gammopathies. Blood 2007; 110: 1497a
  45. Hutchison C, Cockwell P, Basnayake K, Cook M, Harding S, Basu S, et al. Removal of free light chains by extended hemodialysis in patients with cast nephropathy: A phase 1/2 clinical trial. Nephrol Dial Transplant 2007; 22: FP122a
  46. Hutchison CA, Cockwell P, Harding S, Barnett A, Bradwell AR. Quantitative asssessment of serum and urinary polyclonal free light chains in diabetics patients: An early marker of diabetic kidney disease? J Am Soc Nephrol 2007; 18: FPO1010a
  47. Hutchison CA, Cook M, Basu S, Harding S, Basnayake K, Mead G, et al. Renal recovery in myeloma patients with cast nephropathy following light chain removal by hemodialysis. Proceedings of 29th Congress of Nordic Society of Nephrology, Gothenburg 2007: K28a
  48. Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007; 18: 886 – 95 PMID: 17229909
  49. Hutchison CA, Cook M, Basnayake K, Harding S, Bradwell AR, Cockwell P. Free light chain removal hemodialysis increases rates of renal recovery from myeloma kidney. J Am Soc Nephrol 2007; 18: PUB582a
  50. Hutchison CA, Cook M, Basu S, Cockwell P, Basnayake K, R. BA. Combined chemotherapy and high cut-off hemodialysis improve outcomes in multiple myeloma patients with severe renal failure. Blood 2007; 110: 3610a
  51. Hutchison CA, Cook M, Basu S, Harding S, Mead G, Cockwell P, Bradwell AR. High rate of renal recovery in patients with cast nephropathy treated by removal of free light chains using extended hemodialysis: a phase 1/2 clinical trial. Br J Haematol 2007; 137: 137a
  52. Hutchison CA, Harding S, Basnayake K, Townsend J, Landray M, Mead GP, et al. Increased MGUS prevalence in chronic kidney disease patients. Haematologica 2007; 92: PO905a
  53. Hutchison C, Harding S, Bradwell AR, Cockwell P. Serum free light chain removal by high cut-off hemodialysis: Optimising removal and supportive care. J Am Soc Nephrol 2007; 18: SAPO511a
  54. Hutchison C, Harding S, Basnayake K, Mead G, Townsend J, Landray M, et al. Chronic kidney disease patients and renal transplant recipients have a high prevalent rate of MGUS. Nephrol Dial Transplant 2007; 22: SaP072a
  55. Hutchison CA, Cook M, Harding S, Mead G, Cockwell P, Bradwell AR. Renal function recovery following Velcade and extended hemodialysis in patients wiht refactory multiple myeloma and cast nephropathy: case studies. Am J Kidney Dis 2007; 49: 90a
  56. Hutchison CA, Cook M, Harding S, Mead G, Cockwell P, Bradwell AR. Removal of free light chains by extended hemodialysis in patients with cast nephropathy: a phase 1/2 clinical trial. Am J Kidney Dis 2007; 49: 89a
  57. Hutchison CA, Cook M, Harding S, Mead G, Hattersley J, Evans N, et al. Mathematical modelling of free light chain removal by plasma exchange and extended hemodialysis in patients with cast nephropathy. Am J Kidney Dis 2007; 49: 88a
  58. Hutchison CA, Harding S, Mead G, Townsend J, Landray M, Cockwell P, Bradwell AR. Chronic kidney disease patients and renal transplant recipients have an increased incidence of monoclonal gammopathies. Am J Kidney Dis 2007; 49: 87a
  59. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083 – 93 PMID: 17855669
  60. Jagannath S. Value of serum free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology. Clin Lymphoma Myeloma 2007; 7: 518 – 23 PMID: 18021469
  61. Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007; 92: 1351 – 8 PMID: 18024372
  62. Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Tassidou A, et al. Treatment of light chain (AL) amyloidosis and light chain deposition disease (LCDD) with the combination of bortezomib and dexamethasone. Blood 2007; 110: 191a
  63. Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin 2007;57:301-18 PMID: 17855486
  64. Khoriaty RN, Hussein MA, Lally J, Kelly M, Kalaycio M, Baz R. Prediction of response and progression in multiple myeloma (MM) with serum-free light chains (sFLC): Corroboration of the International Myeloma Working Group (IMWG) criteria. J Clin Oncol 2007; 25: 8047a
  65. Kilvington F. Eliminating urine testing during initial investigations for monoclonal gammopathies. Clin Lab Int 2007; 3: 16 – 7
  66. Kruger WH, Kiefer T, Schuler F, Lotze C, Busemann C, Dolken G. Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation. Onkologie 2007; 30: 193 – 5 PMID: 17396042
  67. Kumar S, Pérez WS, Zhang MJ, Bredeson CN, Lacy MQ, Milone G, et al. Comparable outcomes in secretory (SM) versus non-secretory (NSM) multiple myeloma (MM) with autologous hematopoietic stem cell transplantation (AuHCT). Blood 2007; 110: 944a
  68. Kuypers DR, Lerut E, Claes K, Evenepoel P, Vanrenterghem Y. Recurrence of light chain deposit disease after renal allograft transplantation: potential role of rituximab? Transpl Int 2007; 20: 381 – 5 PMID: 17326779
  69. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol 2007; 139: 730 – 43 PMID: 18021088
  70. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356: 2582 - 90 PMID: 17582068
  71. Kyle RA. Serum free light chain assays - their role in multiple myeloma. Touch Briefings 2007; US Hematology: 24 – 7
  72. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Maltezas D, Anagnostopoulos A, Terpos E, et al. The addition of sFLCR improves ISS prognostication in multiple myeloma (MM). Blood 2007; 110: 1490a
  73. Kyrtsonis M-C, Vassilakopoulos TP, Kafasi N, Anagnostopoulos A, Delimpasi S, Terpos E, et al. Prognostic implication of the combination SFLCR + ISS in MM. Haematologica 2007; 92: PO1023a
  74. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007; 137: 240 – 3 PMID: 17408464
  75. Lakshminarayanan R, Li Y, Janatpour K, Beckett L, Jialal I. Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results. Am J Clin Pathol 2007; 127: 746 – 51 PMID: 17439833
  76. Lebovic D, Kendall T, Brozo C, McAllister A, Hari M, Alvi S, et al. Serum free light chain analysis improves monitoring of multiple myeloma patients receiving first-line therapy with the combination of Velcade, Doxil, and Dexamethasone (VDD). Blood 2007; 110: 2736a
  77. Leleu X, Hatjiharissi E, Roccaro AM, Moreau AS, Leduc R, Nelson M, et al. Serum immunoglobulin free light chain (sFLC) is a sensitive marker of response in Waldenstrom Macroglobulinemia (WM). Blood 2007; 110: 1486a
  78. Leleu X, Moreau AS, Manning R, Coiteux V, Darre S, Nelson M, et al. Serum free light chain is a marker of tumor burden and of prognostic impact in Waldenstrom's macroglobulinemia. Haematologica 2007; 92: PO1230a
  79. Leung N, Zeldenrust S, Dispenzieri A, Fervenza F, Gertz M, Kumar S, et al. Serum free light chain and renal biopsy accurately predict renal response to plasma exchange in patients with light chain cast nephropathy. J Am Soc Nephrol 2007; 18: SUP074a
  80. Leung N, Dispenzieri A, Lacy MQ, Kumar SK, Hayman SR, Fervenza FC, et al. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain–associated amyloidosis after autologous stem cell transplantation. Clin J Am Soc Nephrol 2007; 2: 440 – 4
  81. Lewis E, Young C, Watson D. Comparison of western blotting and free light chains in the laboratory diagnosis of multiple sclerosis. Annals Clin Biochem 2007; 44: T51a
  82. Ludwig H, Drach J, Graf H, Lang A, Meran JG. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007; 92: 1411 – 4 PMID: 17768111
  83. Lynch EA, Showell PJ, Johnson-Brett B, Mead GP, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light chains on the Roche Cobas® Integra 400. Clin Chem Lab Med 2007; 45: W089a
  84. Ma ES, Lee ET. A case of IgM paraproteinemia in which serum free light chain values were within reference intervals. Clin Chem 2007; 53: 362 – 3 PMID: 17259251
  85. Martin W, Abraham R, Shanafelt T, Clark RJ, Bone N, Geyer SM, et al. Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Transl Res 2007; 149: 231 – 5 PMID: 17383597
  86. Mayo Medical Laboratories. Laboratory analysis for monoclonal gammopathies. Mayo Communiqué 2007; 32: 1 – 4
  87. Mayo MM, Johns GS. Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias. Contrib Nephrol 2007; 153: 44 – 65 PMID: 17075223
  88. Mazurkiewicz J, Teal T, Reddy R. Evaluation of The Binding Site serum free light chain assay in a DGH: analytical aspects. Annals Clin Biochem 2007; 44: T46a
  89. Mazurkiewicz J, Teal T, Reddy R, Grace R, Gover P. Evaluation of The Binding Site serum free light chain assay in a DGH: clinical aspects. Annals Clin Biochem 2007; 44: T47a
  90. Mehta J, Stein R, Vickrey E, Fellingham S, Singhal S. The relationship between serum free light chain assay and serum immunofixation electrophoresis. Haematologica 2007; 92: PO1010a
  91. Mitchell F, Showell PJ, Harding SJ, Lynch EA, Mead GP, Hutchison CA, Bradwell AR. Correlation of Freelite™ and Cystatin C in chronic kidney disease on The Binding Site SPAplus™ bench-top analyser. Clin Chem Lab Med 2007; 45: T225a
  92. Morgan GJ, Davies FE, Owen RG, Rawstron AC, Bell S, Cocks K, et al. Thalidomide combinations improve response rates; results from the MRC IX study. Blood 2007; 110: 3593a
  93. Morris KL, Tate JR, Gill D, Kennedy G, Wellwood J, Marlton P, et al. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Intern Med J 2007; 37: 456 – 63 PMID: 17547724
  94. Mösbauer U, Ayuk F, Schieder H, Lioznov M, Zander AR, Kroger N. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation. Haematologica 2007; 92: 275 – 6 PMID: 17296589
  95. Nakano T, Komoda T, Nagata A. To the Editor: Author reply; Nakano et al. Clin Chem Lab Med 2006; 44: 522 – 532. Clin Chem Lab Med 2007; 45: 266 – 7
  96. Nakorn TN, Watanaboonyongcharoen P, Suwannabutra S, Theerasaksilp S, Paritpokee N. Early reduction of serum free light chain can predict therapeutic responses in multiple myeloma. Blood 2007; 110: 4742a
  97. Nguyen T, Bocquet J, Troncy J, Chapuis Cellier C. Ability of capillary zone electrophoresis in detecting monoclonal light chains. Haematologica 2007; 92: PO246a
  98. Offidani M, Polloni C, Corvatta L, Busco F, Catarini M, Alesiani F, et al. Usefulness of serum FLC assay in predicting outcome in MM. Haematologica 2007; 92: PO236a
  99. Orlowski R, Sutherland H, Blade J, Miguel JS, Hajek R, Nagler A, et al. Early normalization of serum free light chains is associated with prolonged time to progression following bortezomib {+/-} pegylated liposomal doxorubicin treatment of relapsed/ refractory multiple myeloma. Blood 2007; 110: 2735a
  100. Owen RG, Child JA, Rawstron AC, Bell S, Cocks K, Davies FE, et al. Defining complete response in multiple myeloma: Role of the serum free light chain assay and multiparameter flow cytometry. Blood 2007; 110: 1479a
  101. Palladini G, Nuvolone M, Russo P, Lavatelli F, Perfetti V, Obici L, Merlini G. Treatment of AL amyloidosis guided by biomarkers. Haematologica 2007; 92: PO910a
  102. Pasquali S, De Sanctis LB, Mambelli E, Di Felice A, Wratten M, Santoro A. Coupled plasmafiltration adsorption: A new technology for free light chain removal. J Am Soc Nephrol 2007; 18: FPO691a
  103. Pattenden RJ, Rogers SY, Wenham PR. Serum free light chains; the need to establish local reference intervals. Ann Clin Biochem 2007; 44: 512 – 5 PMID: 17961304
  104. Pika T, Minarik J, Zemanova M, Budikova M, Backovsky J, Scudla V. Relationship of serum free light chain levels and selected biological parameters in patients with multiple myeloma. Haematologica 2007; 92: 1113a
  105. Pineda-Roman M, Tricot G. High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction. Contrib Nephrol 2007; 153: 182 – 94 PMID: 17075230
  106. Polloni C, Offidani M, Corvatta L, Busco F, Catarini M, Alesiani F, et al. Serum FLC as a measure of treatment outcome in MM. Haematologica 2007; 92: PO1014a
  107. Puig N, Chen C, Mikhael J, Reece D, Trudel S, Kukreti V. Spontaneous tumoural regression in a patient with t(4;14) translocation multiple myeloma. A case report. Blood 2007; 110: 4777a
  108. Rajkumar SV, Lacy MQ, Kyle RA. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev 2007; 21: 255 – 65 PMID: 17367905
  109. Ramasamy I. Serum free light chain analysis in B-cell dyscrasias. Ann Clin Lab Sci 2007; 37: 291 – 4 PMID: 17709698
  110. Rawstron AC, Davis B, D. DS, de Tute RM, Kerr MA, Owen RG, Ashcroft AJ. Plasma cell phenotype and SFLC provide independent prognostic information in MGUS. Haematologica 2007; 92: PO907a
  111. Rawstron AC, Jones RA, Ferguson C, Hughes G, Selby P, Reid C, et al. Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience. Br J Haematol 2007; 139: 845 – 8 PMID: 17970800
  112. Rezazadeh A, Laber DA, Sharma VR, Kloecker GH. Amyloidosis presenting with platelet dysfunction and recurrent retroperitoneal hemorrhage (RH). Blood 2007; 110: 3944a
  113. Richards T, Horowitz S, Temple S, Nguyen T, Thomas S, Wang M, et al. Evaluation of MM response by free light chain assay. Haematologica 2007; 92: PO1015a
  114. Richter AG, Harding S, Rimmer S, Pratt G, Huissoon A, Drayson M. Biclonal multiple myeloma with monoclonal free IgG3 heavy chain and kappa free light chains. Blood 2007; 110: 4768a
  115. Ricotta D, Radeghieri A, Amoroso B, Caimi L. Serum free light chains in MM: comparison of 2 assays. Haematologica 2007; 92: PO1018a
  116. Robson E, Mead G, Bradwell A. To the editor: in reply to Nakano et al. Clin Chem Lab Med 2006; 44: 522 – 532. Clin Chem Lab Med 2007; 45: 264 – 5 PMID: 17311521
  117. Robson E, Mead G, Carr-Smith H, Bradwell A. In reply to Tate et al. Clin Chim Acta 2007; 376: 30 – 6. Clin Chim Acta 2007; 380: 247; PMID: 17368602
  118. Robson E, Mead G, Das M, Cavet J, Liakpoulou E. Free Light Chain analysis in patients receiving Bortezomib. Haematologica 2007; 92: PO1019a
  119. Ruchlemer R, Reinus C, Paz E, Cohen A, Melnikov N, Ronson A, Rudensky B. Free light chains, monoclonal proteins, and chronic lymphocytic leukemia. Blood 2007; 110: 4697a
  120. Ruckser R, Tatzreiter G, Kitzweger E, Strecker K, Hraby S, Buxhofer V, et al. Combination therapy with lenalidomide, bortezomib, liposomal doxorubicin and dexamethasone (LBlipDD) may overcome resistance to prior treatment with doxorubicin, lenalidomide, and bortezomib in high-risk multiple myeloma (MM). Blood 2007; 110: 4838a
  121. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial. Blood 2007; 109: 492 – 6 PMID: 16960148
  122. Sheldon J. Free light chains. Ann Clin Biochem 2007; 44: 503 – 5
  123. Showell PJ, Hutchison CA, Cockwell P, Harding S, Mead GP, Mitchell F, Bradwell AR. Correlation of FREELITE and Cystatin C in Chronic Kidney Disease on The Binding Site SPAPLUS bench-top analyser. Clin Chem 2007; 53: C82a
  124. Showell PJ, Lynch EA, Johnson-Brett B, Mead G, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Roche COBAS Integra 400 automated analyser. Clin Chem 2007; 53: C18a
  125. Sinclair D, Wainwright L. How lab staff and the estimation of free light chains can combine to aid the diagnosis of light chain disease. Clin Lab. 2007; 53: 267 – 71. PMID: 17605400
  126. Singhal S, Stein R, Vickrey E, Mehta J. The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias. Blood 2007; 109: 3611 – 2 PMID: 17409349
  127. Singhal S, Stein R, Vickrey E, Fellingham S, Mehta J. Serum free light chain levels in myeloma patients with oligoclonal bands. Haematologica 2007; 92: PO1011a
  128. Snozek CLH, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Clark RJ, et al. Prognostic value of the serum free light chain ratio in patients with newly diagnosed myeloma: proposed incorporation into the international staging system. Blood 2007; 110: 659a
  129. Spradberry D, Holding S. Analytical variability of the Binding Site Freelite assay in serum. Presented at IBMS Congress 2007
  130. Storr M, Goehl H, Cockwell P, Hutchison C, Bradwell A. Efficient removal of immunoglobulin free light chains by hemodialysis using a novel high cut-off membrane. Blood purif 2007; 25: O17a
  131. Sui WW, Yao HJ, Wang YF, Wang L, Zhang K, Xu Y, Qiu LG. Assessment of serum free light chain of patients with multiple myeloma and clinical significance thereof. Zhonghua Yi Xue Za Zhi 2007; 87: 3158 – 60 PMID: 18269880
  132. Sweeting R, Notkin A, Leung N, Ballard H, Pillon L. Approach to acute renal failure in biopsy proven myeloma cast nephropathy. Is there a role for plasmapheresis? J Am Soc Nephrol 2007; 18: PUB570a
  133. Tan T-S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, et al. Melphalan and dexamethasone is an effective therapy for primary systemic amyloidosis. Blood 2007; 110: 3608a
  134. Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 2007; 376: 30 – 6 PMID: 16945362
  135. Trieu Y, Xu W, Chen C, Kukreti V, Mikhael J, Trudel S, Reece D. Evaluation of serum free light chains and outcome in multiple myeloma patients with an intact monoclonal immunoglobulin treatment with autologous stem cell treansplantation. Haematologica 2007; 92: PO1021a
  136. Trigo F, Guimaraes C, Bodas A, Teixeira-Pinto A, Guimaraes JE. Serum free light chain assessment in 311 patients with gammopathy. Blood 2007; 110: 4750a
  137. Van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827 – 32 PMID: 17416735
  138. Wechalekar AD, Goodman HJB, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457 – 64 PMID: 16990593
  139. Wolff F, Thiry C, Willems D. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy. Clin Biochem 2007; 40: 351 – 4 PMID: 17239359
  140. Zarabpouri F, Popov J, Montana L, Ferruzza AS, Naides SJ. Role of nephelometry-based detection of serum free light chain kappa/ lambda in diagnosis of multiple myeloma. Clin Chem 2007; 53: C148a
  141. Zibrat S, Gloria CT, Joseph L, W. MR. Analytical and clinical performance limtiations of immunoturbidimetric vs. immunonephelometric methods for free light chain analysis in serum. Clin Chem 2007; 53: B79a
  142. Zinke-Cerwenka W, Stojakovic T, Scharnagl H, Wassertheurer S, Linkesch W. Therapy response by decrease of free light chain concentration in multiple myeloma patients treated with bortezomib/ doxorubicin/ dexamethasone as first-line therapy. Blood 2007; 110: 4818a

2008

  1. Aggarwal R, Mikolaitis R, Alvi S, Assi L, Block J, Jolly M, Sequeira W. Serum free light chains as a biomarker in systemic lupus erythematosus. Presented at American College of Rheumatology Annual Scientific Meeting 2008: 1089a
  2. Allen S, Vickrey E, Mehta J, Singhal S. The relationship between serum free light chain levels and serum immunofixation electrophoresis: Implications for the definition of "Stringent CR" in myeloma. Blood 2008; 112: 2724a
  3. Alvi A, Harding S, Pietrantuono A, Berard A. Serum free light chain immunoassay (Freelite) as an adjunct to SPE and IFE in the detection of multiple myeloma and other B cell malignancies. Hematology meeting reports 2008; 2: C25a
  4. Bachmann U, Schindler R, Storr M, Kahl A, Joerres A, Sturm I. Combination of bortezomib-based chemotherapy and extracorporeal free light chain removal for treating cast nephropathy in multiple myeloma. Nephrol Dial Transplant 2008; 1: 106 – 8
  5. Barlogie B, van Rhee F, Shaughnessy JD, Jr., Epstein J, Yaccoby S, Pineda-Roman M, et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 2008; 112: 3122 – 5 PMID: 18669874
  6. Basnayake K, Hutchison C, Kamel D, Sheaff M, Ashman N, Oakervee H, et al. Resolution of cast nephropathy following free light chain removal by hemodialysis in a patient with multiple myeloma. Am J Kidney Dis 2008; 51: 24a
  7. Basnayake K, Hutchison C, Kamel D, Sheaff M, Ashman N, Cook M, et al. Resolution of cast nephropathy following free light chain removal by haemodialysis in a patient with multiple myeloma: a case report. J Med Case Reports 2008; 2: 380 PMID: 19068112
  8. Basnayake K, Cheung CK, Hutchison C, Kamel D, Sheaff M, Fuggle W, et al. The differential evolution of renal scarring in myeloma kidney despite early reductions in free light chains. Hematology meeting reports 2008; 2: E35a
  9. Basnayake K, Ghonemy T, Hutchison C, Bradwell AR, Cockwell P. Immunoglobulin free light chains in situ in patients with chronic kidney disease. Hematology meeting reports 2008; 2: E34a
  10. Basnayake K, Hutchison C, Kamel D, Sheaff M, Fuggle W, Cook M, et al. Rapid reduction of serum free light chains by high cut-off haemodialysis in cast nephropathy: supporting histological evidence from two cases. Renal Association Annual Congress 2008: P60a
  11. Bergner R, Vilardi S, Hoffmann M, Uppenkamp M. Free light chains in urine - an additional diagnostic advantage? Hematology meeting reports 2008; 2: B7a
  12. Bernon H, Karame A, Dimet I, Villar E, Regad-Pellagru AL, Bienvenu J. About a case of lambda free light chain multiple myeloma treated by bortezomib chemotherapy and long haemodialysis on polymethylmethacrylate membrane. Hematology meeting reports 2008; 2: E40a
  13. Bidet A, Marit G, Berard AM. [Clinical value of the blood measurement of the free light chains of immunoglobulins]. Ann Biol Clin (Paris) 2008; 66: 427 – 31 PMID: 18725344
  14. Blade J, Rosinol L. SMM: Towards pretter predictors of progression. Blood 2008; 111: 479 – 80
  15. Blade J, Rosinol L, Cibeira MT, de Larrea CF. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 2008; 22: 1651 – 7 PMID: 18668131
  16. Bochtler T, Hegenbart U, Heiss C, Benner A, Cremer F, Volkmann M, et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica 2008; 93: 459 – 62 PMID: 18287137
  17. Brandhorst D, Bockling M, Sammet C, Daniels R, Schuett P, Buttkereit U, et al. Monoclonal free light chains and renal dysfunction in multiple myeloma. Hematology meeting reports 2008; 2: E42a
  18. Bruck P, Atta J, Hildegund S-E, Bohme A, Oremek GM. Lambda and kappa free light chains in haematologic patients. Clin Exp Med Lett 2008; 49: 19 – 22
  19. Burg M, Niederstadt C, Dotzeva E, Kliem V. Serum free light chains in patients with renal failure stage II-V of native kidneys or renal transplants. Renal Association Annual Congress 2008: PUB249a
  20. Callis M, Garcia L, Gironella M, Rodrigo MJ, Garcia E, Castella D. Serum free light chain reference intervals. A study of 133 blood donors. Haematologica 2008; 93: 1332a
  21. Callis M, Garcia L, Gironella M, Rodrigo MJ, Garcia E, Castella D. Serum fee light chain reference intervals. A study of 133 blood donors. Hematology meeting reports 2008; 2: B6a
  22. Chan PC, Lem - Ragosnig B, Oczak M, Rozmanc M. Follow-up investigations for 'nephrotic syndrome' pattern in serum protein electrophoresis. Clin Biochem 2008; 41: 108a
  23. Chattopadhyay A, Nath UK, De R, Singh A, Sanyal S, Chatterjee SK, Chaudhuri U. Primary plasma cell leukemia with initial cutaneous involvement and IgA biclonal gammopathy. Ann Hematol 2008; 87: 249 – 51 PMID: 17909800
  24. Chen HF, Hou J, Yuan ZG, Wang DX, Fu WJ, Chen YB. [Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2008; 29: 113 – 6
  25. Civini S, Radeghieri A, Amoroso B, Caimi L, Ricotta D. Free light chain behaviour in sera from patients producing cryoglobulins. Hematology meeting reports 2008; 2: C16a
  26. Clark WF, Garg AX. Plasma exchange for myeloma kidney: cast(s) away? Kidney Int 2008; 73: 1211 – 3 PMID: 18480853
  27. Coriu D, Talmaci R, Badelita S, Dobrea D, Dogaru M, Ostroveanu D, et al. Clinical study of 35 cases of primary systemic amyloidosis. Haematologica 2008; 93: 1301a
  28. Davern S, Tang LX, Williams TK, Macy SD, Wall JS, Weiss DT, Solomon A. Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol 2008; 130: 702 – 11 PMID: 18854262
  29. De Filippi R, Laccarino G, Frigeri F, Di Francia R, Amoroso B, Marchei A, Pinto A. The presence of serum free-immunoglobulin light chains and abnormal k/l ratios is a frequent finding in patients with Hodgkin's and B-cell non-Hodgkin's lymphoma. Hematology meeting reports 2008; 2: C18a
  30. de Fost M, Out TA, de Wilde FA, Tjin EP, Pals ST, van Oers MH, et al. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol 2008; 87: 439 – 49 PMID: 18274746
  31. Decaux O, Briand PY, Guenet L, Ropert M, Sebillot M, Grosbois B. An abnormal serum free light chain ratio is associated with higher monoclonal concentration and bone marrow plasmacytosis in a French cohort of patients with monoclonal gammopathy of undetermined significance. Hematology meeting reports 2008; 2: C22a
  32. Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008; 22: 1485 – 93 PMID: 18528426
  33. Dispenzieri A. Impact of serum free light chain evaluation in monoclonal gammopathies. Hematology Education: the education program for the annual congress of the European Hematology Association 2008; 2: 279 – 86
  34. Dispenzieri A. To the editor: Is early, deep free light chain response really an adverse prognostic factor? Blood 2008; 111: 2490 – 1
  35. Dispenzieri A. How and when I use serum free light chain tests. Hematology meeting reports 2008; 2: 4 – 6
  36. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008; 111: 785 – 9 PMID: 17942755
  37. Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, Degoey R, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008; 111: 4908 – 15 PMID: 18364469
  38. Dotzeva E, Niederstadt C, Burg M, Kliem V. Serum free light chains in patients with renal failure stage II-V of native kidneys or renal transplants. Hematology meeting reports 2008; 2: E43a
  39. Doyle A, Soutar R, Geddes CC. Multiple myeloma in chronic kidney disease. Utility of discretionary screening using serum electrophoresis. Nephron Clin Pract 2008; 111: c7 - c11 PMID: 19033691
  40. Drengler T, Kumar S, Gertz M, Lacy M, Katzmann J, Hayman S, et al. Serum immunoglobulin free light chain measurements provide insight into disease biology in patients with POEMS syndrome. Proceedings of Portuguese myeloma meeting 2008
  41. Encinas Madrazo A, González García ME, Cepeda Piorno J, González Huerta AJ, Fernández Rodríguez E. Serum free light chains: Clinical utility. An Med Interna 2008; 25: 249 – 50
  42. Espinilla HA. Determinaciande valories esperados de referencia Kappa libre en suero, Lambda libre in suero y Kappa/Lambda suero en nuestro departamento de salud. Rev Lab Clinic 2008; s1
  43. Exner I, Eigner M, Kraus R, Leithner C. Acute renal failure because of light chain deposition disease and its successful combined treatment with chemotherapy and dialysis with high flux membrane. Hematology meeting reports 2008; 2: E36a
  44. Forsyth J, Hill P. Serum free light chains. Reply to Beetham et al. Can serum free light chains replace urine electrophoresis? Ann Clin Biochem 2008; 45: 444 – 5
  45. Forsyth J, Mayne S, Lawson N. A rare case of polyclonal Mu Heavy Chain Disease. Ann Clin Biochem 2008; 45: 4a
  46. Gertz MA. Current therapy of myeloma induced renal failure. Leuk Lymphoma 2008; 49: 833 - 4 PMID: 18452070
  47. Giroux M, Sheridan B. The serum free light chain assay: an alternative to Bence Jones protein analysis in screening for monoclonal gammopathies. Hematology meeting reports 2008; 2: C21a
  48. Giroux M, Sheridan B. The serum free light chain assay: An alternative to Bence Jones protein analysis in screening for monoclonal gammopathy. Clin Biochem 2008; 41: 113a
  49. Gottenberg JE, Dillon SR, Combe B, Harder B, Hahne M, Morel J, et al. Serum April levels correlate with disease activity and severity of radiologic lesions in early rheumatoid arthritis patients: Results from the French multicenter prospective cohort study (espoir) Presented at American College of Rheumatology Annual Scientific Meeting 2008: 328a
  50. Granátová J, Bolková M, Fantová L, Hornová L, Mašková Z, Horák J, Lánská V. Free light chains of immunoglobulins in patient with renal insufficiency. Klin Biochem Metab 2008; 16: 106 – 10
  51. Graubaum K, Heymann GA, Hunger T, Ostapowicz B. Case report: Shift in secretion from intact immunoglobulin to free light chains in multiple myeloma at relapse: early detection by free light chain assay. Hematology meeting reports 2008; 2: D26a
  52. Gregorini GA, Mazzola G, Valerio F, Econimo L, Gasparotti I, Ricotta D, Cancarini G. Extensive use of serum free light chain test in patients with nephropathy increases the diagnosis number of AL amyloidosis and light chain deposition disease. Hematology meeting reports 2008; 2: E41a
  53. Harding S, Pratt G, Holder R, Pepper C, Fegan C, Oscier D, Mead G. Abnormal serum free light chain ratios are associated with poor survival in patients with chronic lymphocytic leukemia. Hematology meeting reports 2008; 2: C20a
  54. Harding S, Pratt G, Pepper C, Fegan C, Oscier D, Mead G. Abnormal serum free light chain ratios are associated with poor survival in patients with chronic lymphocytic leukemia. Lymphoma & Myeloma congress 2008
  55. Harding SJ, Pratt G, Holder R, Fegan C, Pepper C, Oscier D, Mead GP. Abnormal serum free light chain ratios in chronic lymphocytic leukaemia are significantly associated with earlier disease specific death. Haematologica 2008; 93: 89a
  56. Harousseau JL, Dreyling M. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19: ii55 – 7 PMID: 18456769
  57. Hassoun H, Flombaum C, D'Agati VD, Rafferty BT, Cohen A, Klimek VM, et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 2008; 42: 405 – 12 PMID: 18574442
  58. Hatjiharissi E, Ciccarelli BT, Ioakimidis L, Borok R, Soumerai JD, Manning RJ, et al. Serum Immunoglobulin free light chains as markers of disease burden and response to treatment in patients with Waldenstrom's macroglobulinemia. J Clin Oncol 2008; 26: 8617a
  59. Hobbs JA, Kilvington F, Sharp K, Harding S, Drayson M. Incidence of light chain escape in UK MRC Myeloma VII trial. Hematology meeting reports 2008; 2: D31a
  60. Hobbs JA, Kilvington F, Sharp K, Harding S, Drayson M, Bradwell AR, Mead GP. Incidence of light chain escape in UK MRC Myeloma VII Trial. Clin Chem 2008; 54: C109a
  61. Hobbs JAR, Sharp K, Harding SJ, Drayson M, Bradwell AR, Mead GP. Incidence of light chain escape in UK MRC myeloma VII trial Haematologica 2008; 93: 672a
  62. Hodkinson F, Galligan L, Drain S, Catherwood MA, Morris TCM, Drake MB, et al. Investigation of plasma cell dyscrasias with low level plasma cell aspirate involvement. Haematologica 2008; 93: 1205a
  63. Hoffman-Snyder C, Smith BE. Neuromuscular disorders associated with paraproteinemia. Phys Med Rehabil Clin N Am 2008; 19: 61 – 79 PMID: 18194750
  64. Hutchison C, Basnayake K, Bradwell A, Cockwell P. Serum free light chain removal by high cut-off hemodialysis: Optimising removal and supportive care. Renal Association Annual Congress 2008: P129a
  65. Hutchison C, Basnayake K, Cockwell P. Chronic kidney disease patients and renal transplant recipients have a high prevalence of MGUS. Hematology meeting reports 2008; 2: E38a
  66. Hutchison C, Basnayake K, Cook M, Bradwell A, Cockwell P. High rates of renal recovery and patient survival in myeloma kidney using free light chain removal hemodialysis. Renal Association Annual Congress 2008: P245a
  67. Hutchison C, Basnayake K, Cook M, Bradwell A, Cockwell P. Free light chain removal hemodialysis increases renal recovery rate and improves patient suvival in patients with cast nephropathy. Nephrol Dial Transplant 2008; 23: S0019a
  68. Hutchison C, Basnayake K, Cook M, Cockwell P, Bradwell AR. High renal recovery rate from cast nephropathy following free light chain removal hemodialysis. Am J Kidney Dis 2008; 49: B47a
  69. Hutchison C, Basnayake K, Plant T, Drayson M, Cockwell P. Serum free light chain measurement aids the diagnosis of myeloma in patients with acute renal failure. Hematology meeting reports 2008; 2: E39a
  70. Hutchison C, Cook M, Basnayake K, Cockwell P, Bradwell A. Free light chain removal hemodialysis increases renal recovery rate and improves patient survival in patients with cast nephropathy. Lymphoma & Myeloma congress 2008
  71. Hutchison C, Drayson M, Basnayake K, Mead G, Bradwell A, Plant T, Cockwell P. Serum free light chain measurement aids the diagnosis of myeloma in patients with acute renal failure. Renal Association Annual Congress 2008: SA-PO2498a
  72. Hutchison C, Grima DT. Long-term clinical outcomes and cost-effectiveness of hemodialysis with the HCO 1100 dialyzer versus standard hemodialysis in patients with renal failure secondary to myeloma. Renal Association Annual Congress 2008: SA-PO3060a
  73. Hutchison C, Hewins P, Landray MJ, Townsend J, Cockwell P. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Hematology meeting reports 2008; 2: E37a
  74. Hutchison C, Meryon I, Drayson M, Bradwell A, Cockwell P. High cut-off hemodialysis lowers inflammatory status in chronic dialysis patients. Renal Association Annual Congress 2008: TH-PO707a
  75. Hutchison C, Plant T, Drayson M, Basnayake K, Cockwell P. Serum free light chains - a new highly sensitive and specific immunoassay for detecting monoclonal gammopathies in patients with acute renal failure. Renal Association Annual Congress 2008: P67a
  76. Hutchison C, Plant T, Drayson M, Cockwell P, Basnayake K, Harding S, et al. Serum immunoassay is highly sensitive and specific for the diagnosis of monoclonal free light chains in patients with severe renal failure. Nephrol Dial Transplant 2008; 23: SP113a
  77. Hutchison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell AR, Cockwell P. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 2008; 9: 55 PMID: 18822172
  78. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, Cockwell P. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1684 – 90 PMID: 18945993
  79. Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, Cockwell P. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs 2008; 32: 910 – 7 PMID: 19133018
  80. Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 2008; 9: 11 PMID: 18808676
  81. Hutchison CA, Cockwell P, Harding S, Mead GP, Bradwell AR, Barnett AH. Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: an early marker of diabetic kidney disease? Expert Opin Ther Targets 2008;12: 667 – 76 PMID: 18479214
  82. Itzykson R, Le Garff-Tavernier ML, Katsahian S, DiemertM-C, Musset L, Leblond V. Serum Free Light Chain Elevation Is Associated with a Shorter Time to Treatment in Waldenstrom’s Macroglobulinemia. Haematologica. 2008 May;93(5):793-4. PMID: 18450739
  83. Jiminez J. Utilidad de la determinacion de cedenas ligera libres ensuero para el diagnostico y monitorizacion de gammopatias monoclonales. Rev Lab Clinic 2008; s1
  84. Jung S, Kim M, Lim J, Kim Y, Han K, Min CK, Min WS. Serum free light chains for diagnosis and follow-up of multiple myeloma. Korean J Lab Med 2008; 28: 169 – 73 PMID: 18594166
  85. Kaplan B, Ramirez-Alvarado M, Dispenzieri A, Zeldenrust SR, Leung N, Livneh A, Gallo G. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties. Clin Chem Lab Med 2008; 46: 335 – 41 PMID: 18254719
  86. Kar R, Dutta S, Bhargava R, Kumar R, Pati HP. Immunoglobulin free light chains: do they have a role in plasma cell leukemia? Hematology 2008;13:344-7 PMID: 19055862
  87. Katzmann JA, Dispenzieri A. Editorial: Screening algorithms for monoclonal gammopathies. Clin Chem 2008; 54: 1753 – 5
  88. Katzmann JA. Laboratory strategies for detecting Multiple Myeloma. Advance for Administrators of the Laboratory 2008; 17: 46
  89. Kimby E. Treatment of Waldenstrom's macroglobulinaemia. Hematology Education: the education program for the annual congress of the European Hematology Association 2008; 2: 294 – 301
  90. Krizalkovicova V, Maisnar V, Pour L, Radocha J, Hajek R. [Monoclonal gammopathies of undetermined significance]. Klin Onkol 2008; 21: 160 – 4 PMID: 19102222
  91. Kumar K, Dispenzieri A, Lacy M, Hayman S, Buadi F, Zeldenrust S, et al. A novel staging system for light chain amyloidosis incorporating free light chain levels. Hematology meeting reports 2008; 2: C19a
  92. Kumar K, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, et al. A novel staging system for light chain amyloidosis incorporating free light chain levels. Haematologica 2008; 93: 917a
  93. Kumar S, Dispenzieri A, Clark R, Larson D, Colby CL, Zeldenrust S, et al. Serum immunoglobulin free light chain in primary amyloidosis: Prognostic value and correlations with clinical features. Blood 2008; 112: 2733a
  94. Kumar S, Dispenzieri A, Larson D, Colby CL, Kyle R, Gertz M, Rajkumar SV. Normalization of the serum free light chain (FLC) ratio is associated with superior overall survival among myeloma patients achieving immunofixation negative sate: Results support incorporation of serum FLC ratio in stringent CR definition. Blood 2008; 112: 1692a
  95. Kumar S, Perez WS, Zhang MJ, Ballen K, Bashey A, To LB, et al. Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 1134 – 40 PMID: 18804043
  96. Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann J, Snyder M, et al. Association of high levels of free light chain and the presence of Igh translocations in multiple myeloma and prognostic implications. Blood 2008; 112: 1677a
  97. Kyle RA. The role of serum free light chains in monoclonal gammopathy of undetermined significance, solitary plasmacytoma of bone and smoldering multiple myeloma. Hematology meeting reports 2008; 2: 11 – 2
  98. Kyrtsonis MC, Maltezas D, Repousis P, Vassilakopoulos KT, Tzenou T, Papanikolaou X, et al. Possible role of myeloma biologically important cytokines in the inappropriate light chain secretion of malignant plasma cells. Hematology meeting reports 2008; 2: B13a
  99. Kyrtsonis MC, Tzenou T, Vassilakopoulos N, Kafasi N, Sachanas S, Maltezas D, et al. Free light chain ratio in the serum of patients with Waldenstroms macroglobulinemia at diagnosis. Hematology meeting reports 2008; 2: C24a
  100. Kyrtsonis MC, Vassilakopoulos D, Maltezas D, Kafasi N, Terpos E, Elefterakis-Papaiakovou E, et al. Suggested risk-stratification models including serum free light chain ratio for improved prognostication in mulitple myeloma. Hematology meeting reports 2008; 2: C23a
  101. Kyrtsonis M-C, Vassilakopoulos TP, Tzenou T, Kafasi N, Sachanas S, Koulieris E, et al. Serum free light chains in Waldenstrom's Macroglobulinaemia (WM) patients at diagnosis. Haematologica 2008; 93: 1057a
  102. Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Kyle RA, Rajkumar SV, et al. Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. J Heart Lung Transplant 2008; 27: 823 – 9 PMID: 18656793
  103. Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, Goldsmith Y, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008; 143: 369 – 73 PMID: 18691169
  104. Leleu X, Moreau AS, Hennache B, Dupire S, Faucompret JL, Facon T, et al. Serum free light chain immunoassays measurements for monitoring solitary bone plasmacytoma. Haematologica 2008; 91: PO410a
  105. Leleu X, Moreau AS, Weller E, Roccaro AM, Coiteux V, Manning R, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma 2008; 49: 1104 – 7 PMID: 18452095
  106. Leleu X, Roccaro AM, Leduc R, Poulain S, Moreau A-S, Gay J, et al. Early response using serum immunoglobulin free light chain (sFLC) measurement predicts response to therapy in Waldenstrom Macroglobulinemia (WM). Blood 2008; 112: 3755a
  107. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008; 73: 1282 – 8 PMID: 18385667
  108. Lonial S, Gertz MA. To the editor: Eliminating the complete response penalty from myeloma response assessment. Blood 2008; 111: 3297 – 8 PMID: 18332233
  109. Lopez de la Guila A, Pollmar IR, Salvatierra MG, Rodrigo E, Martin-Salces M, De Paz R, et al. IgD multple myeloma: Case report. Hematology meeting reports 2008; 2: D28a
  110. Ludwig J, Aulmann M, Zorn M, Nawroth P. Evaluation of the SPAPLUS for serum free light chain measurement. Hematology meeting reports 2008; 2: A1a
  111. Lynch EA, Showell PJ, Johnson-Brett B, Mead GP, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light chains on the Roche cobas c501. Clin Chem 2008; 54: C93a
  112. Lynch EA, Showell PJ, Johnson-Brett B, Mead GP, Bradwell AR. Evalutaion of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Roche cobas Integra 800. Clin Chem 2008; 54: C94a
  113. Lynch EA, Showell PJ, Kaur A, Mead GP, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Beckman Synchron LX20 Pro and Beckman UniCel DxC Synchron. Clin Chem 2008; 54: C97a
  114. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular Magnetic Resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008; 10: 54 PMID: 19032744
  115. Maisnar V, Hájek R. Revision of criteria for the diagnosis and evaluation of response to therapy in multiple myeloma Klin Biochem Metab 2008; 16: 84 – 8
  116. Mao XB, Chen XQ, Zhai YP, Liang R, Gao GX, Ma GG, et al. [Measurement of serum free light chains and its clinical significance in 20 newly diagnosed patients of multiple myeloma.]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008; 16: 829 – 32 PMID: 18718070
  117. Marionneaux S, Zetlmeisl M, van Hoeven KH, Fagan D, Elkins B, Shulman S. Analytical evaluation of kappa and lambda serum free light chains on The Binding Site SPAplus TM. Clin Chem 2008; 54: C79a
  118. Mark T, Jayabalan D, Coleman M, Pearse RN, Wang YL, Lent R, et al. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol 2008; 143: 654 – 60 PMID: 18950461
  119. Matsuda M, Gono T, Katoh N, Yoshida T, Tazawa K, Shimojima Y, et al. Nephrotic syndrome due to primary systemic AL amyloidosis, successfully treated with VAD (vincristine, doxorubicin and dexamethasone) alone. Intern Med 2008; 47: 543 – 9 PMID: 18344643
  120. Matters DJ, Smith L. Comparison of New Scientific Company and Binding Site kits for free light chain measurements in serum. Hematology meeting reports 2008; 2: B14a
  121. Matters DJ, Solanki M, Jones R, Rose S. Statistical analysis of free light chain results between eight nephelometirc and turbidimetric platforms. Hematology meeting reports 2008; 2: A5a
  122. Matters DJ, Solanki M, Jones R, Rose S, Carr-Smith H, Bradwell AR. Statistical analysis of free light chain results between seven nephelometric and turbidimetric platforms. Clin Chem 2008; 54: C107a
  123. McCudden CR, Hammett-Stabler CA. A case of hook effect in the serum free light chain assay using the Olympus AU400e. Clin Biochem 2008; 41: 148a
  124. Mead G, Harding S, Pratt G, Basu S, Jacob A, Beardsmore C, Bradwell AR. Serum immunoglobulin and free light chain abnormalities in non Hodgkin Lymphoma. Ann Oncol 2008; 19: 315a
  125. Mead GP, Carr-Smith HD, Bradwell AR. Free light chains. Reply to Beetham et al., Can serum free light chains replace urine electrophoresis? Ann Clin Biochem 2008; 45: 444
  126. Mead GP, Hobbs JAR, Sharp K, Harding S, Drayson M. Incidence of light chain escape in myeloma patients at relapse. Br J Haematol 2008; 141: 98a
  127. Mead GP, Stubbs PD, Goodman HJB, Hawkins PN. Comparison of serum versus urine for the identification of monoclonal free light chain production in 219 patients with AL amyloidosis. Hematology meeting reports 2008; 2: B12a
  128. Merlini G, Palladini G. Advances in AL amyloidosis. Hematology Education: the education program for the annual congress of the European Hematology Association 2008; 2: 287 – 93
  129. Mignot A, Bridoux F, Thierry A, Varnous S, Pujo M, Delcourt A, et al. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis. Haematologica 2008; 93: e32 – 5 PMID: 18310532
  130. Mignot A, Varnous S, Redonnet M, Jaccard A, Epailly E, Vermes E, et al. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis 2008; 101: 523 – 32 PMID: 19041836
  131. Morandeira F, Soriano A, Quandt E, Castro P, Ruiz E. Oriol A. Pujol R, Herrero MJ. Comparacion de 2 ensayos para la determination de cadenas ligeras libres en suero en pacientes con gammapatia monoclonal. Immunologia 2008; 27: 118a
  132. Morgera S, Kleeberg L, Jakob C, Schneider M, Muller C, Kaiser M, et al. Elimination of serum free light chains by novel replacement strategies in combination with chemotherapy in patients with multiple myeloma and kappa light chain nephropathy. Hematology meeting reports 2008; 2: E34a
  133. Munshi NC. Investigative tools for diagnosis and management. Hematology Am Soc Hematol Educ Program 2008: 298 – 305
  134. Nam M, McRoberts J, Moody M, Al Swanamy T, Poynton C. Light chain escape from paraproteinemia - myth or reality? Hematology meeting reports 2008; 2: D32a
  135. Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008; 111: 1101 – 9 PMID: 17989313
  136. Offidani M, Polloni C, Piersantelli M-N, Corvatta L, Gentili S, Catarini M, et al. Impact of free light chains ratio normalization on response duration in multiple myeloma (MM) patients treated with new drugs. Haematologica 2008; 93: 1476a
  137. Park M, Song W, Kim J, Hang H, Lee K. Diagnostic performance of serum free light chain assay in monoclonal gammopathies. Clin Chem 2008; 54: C108a
  138. Pasquali S, Mancini E, Santoro A. Removal of free circulating light chains (LC) by a high cut-off membrane: Different dialysis strategies. Renal Association Annual Congress 2008: F-PO1560a
  139. Piehler AP, Gulbrandsen N, Kierulf P, Urdal P. Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population. Clin Chem 2008; 54: 1823 – 30 PMID: 18801937
  140. Pika T, Minarik J, Schneiderka P, Budikova M, Langova K, Lochman P, et al. The correlation of serum immunoglobulin free light chain levels and selected biological markers in multiple myeloma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008; 152: 61 – 4 PMID: 18795076
  141. Pika T, Minařík J, Zemanová M, Schneiderka P, Bačovský J, Šlézar J, Ščudla V. Serum free light chain immunoglobulin levels in multiple myeloma and monoclonal gammopathy of undetermined significance. Klin Biochem Metab 2008; 16: 102 – 5
  142. Pillon L, Sweeting RS, Arora A, Notkin A, Ballard HS, Wieczorek RL, Leung N. Approach to acute renal failure in biopsy proven myeloma cast nephropathy: is there still a role for plasmapheresis? Kidney Int 2008; 74: 956 – 61 PMID: 18418353
  143. Pinto A, De Filippi R, Iaccarino G, Di Francia R, Distinto M, Frigeri F, et al. Abnormalities in serum free-immunoglobulin light chains show a high and differential frequency among WHO subtypes of B-cell non-Hodgkin's lymphoma (NHL) and may turn of value for therapeutic monitoring: A study of 354 newly diagnosed patients. Blood 2008; 112: 2813a
  144. Pisani F, Cordone I, Dessanti ML, Cigliana G, Frollano B, Masi S, et al. Bortezomib, liposomal doxorubicin and dexamethasone regimen for relapsed or refractory multiple myeloma and introduction of serum free light chains (sFLC) in response monitoring: Preliminary data. Haematologica 2008; 93: 1106a
  145. Popat R, Oakervee H, Williams C, Cook M, Craddock C, Basu S, et al. Bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma. Haematologica 2008; 93: 918a
  146. Pratt G, Harding S, Holder R, Fegan C, Pepper C, Oscier D, Mead G. Abnormal serum free light chain ratios are associated with poor survival in patients with chronic lymphocytic leukaemia. Br J Haematol 2008; 141: 80a
  147. Pratt G, Holding S. More studies are needed to assess the performance of serum free light chain measurement for the diagnosis of B-cell disorders in routine clinical practice – response to Vermeersch et al. Br J Haematol 2008; 143: 145 – 6
  148. Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol 2008; 141: 413 – 22 PMID: 18318757
  149. Pratt G, Mead G, Basu S, Jacobs A, Holder R, Fegan C, et al. Abnormal serum free light chain ratios are associated with earlier time to first treatment and poor survival in patients with chronic lymphocytic leukaemia. Blood 2008; 112: 3141a
  150. Presslauer S, Milosavljevic D, Brucke T, Bayer P, Hubl W. Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol 2008; 255: 1508 – 14 18685917 PMID: 18685917
  151. Recasens V, Rubio-Escuin R, Rubio-Martinez A, Pascual T, Lopez N, Sanjuan M, Giraldo P. Serum free light chains profile as early biomarker with predictive value after autologous transplant in multiple myeloma. Blood 2008; 112: 5142a
  152. Recasens V, Rubio-Escuin R, Rubio-Martinez A, Rodriguez T, Lopez N, Giraldo P. Early predictive value of serum free light chains profile in relapsed of multiple myeloma after autologous transplant. Hematology meeting reports 2008; 2: D33a
  153. Robin H, Gaertner R, Parton A, Zetlmeisl M, Garcia A, Kuus-Reichel K. Utility of serum free light chain analysis in the diagnosis of monoclonal gammopathies in a community hospital. Hematology meeting reports 2008; 2: C17a
  154. Rodriguez GP, Jimenez JJ, Rodriguez MJR, de Carvalho NB, Manzanal RM, de Larramendi CH, Godoy PS. Patient with multiple myeloma, in extramedullary relapse associated to light chain excretion and disappearing of intact immunoglobulin 'light chain escape'. Hematology meeting reports 2008; 2: D29a
  155. Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C, et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 2008; 49: 890 – 5 PMID: 18464107
  156. Sackmann F, Pavlovsky AP, Corrado C, Pizzolato M, Alejandre M, Pavlovsky S. Prognostic factors in monoclonal gammopathy of undetermined significance. Haematologica 2008; 93: 153 – 4 PMID: 18166806
  157. Schonland SO, Hansmann J, Mechtersheimer G, Goldschmidt H, Ho AD, Hegenbart U. Bone involvement in patients with systemic AL amyloidosis mimics lytic myeloma bone disease. Haematologica 2008; 93: 955 – 6 PMID: 18515883
  158. Ščudla V, Schneiderka P, Pika T, Minařík J, Bačovský J, Farbiaková V. Clinical importance of evaluating serum levels of free light chains of immunoglobulins in monoclonal gammopathies Klin Biochem Metab 2008; 16: 76 – 83
  159. Seldin DC, Ward JE. Serum free light chain analysis, 4th Edition. Amyloid 2008; 15: 142 – 3
  160. Shaheen SP, Talwalkar SS, Medeiros LJ. Multiple myeloma and immunosecretory disorders: an update. Adv Anat Pathol 2008; 15: 196 – 210 PMID: 18580096
  161. Sharp K, Emond JP, Giroux M, Steiner A, Russ G, Harding S. Serum free light chain measurements by electrophoretic and nephelometric methods may differ due to the presence of aggregated light chains. Hematology meeting reports 2008; 2: B11a
  162. Sheldon J. Free light chains: author's response. Ann Clin Biochem 2008; 45: 445 – 6 PMID: 18583639
  163. Showell PJ, Lynch EA, Johnson-Brett B. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light chains on the Roche COBAS C501. Hematology meeting reports 2008; 2: A2a
  164. Showell PJ, Lynch EA, Johnson-Brett B. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Roche COBAS INTEGRA 800. Hematology meeting reports 2008; 2: A3a
  165. Showell PJ, Lynch EA, Mitchell F. Comparison of serum free immunoglobulin light chain assays on eight nephelometric/ turbidimetric analysers. Hematology meeting reports 2008; 2: A4a
  166. Showell PJ, Lynch EA, Mitchell F, Mead GP, Bradwell AR. Comparison of serum free immunoglobulin light-chain assays on eight Nephelometric/Turbidimetric analysers. Clin Chem 2008; 54: C92a
  167. Siegel DS, McBride L, Lendvai N, Gonsky J, Berges T, Schillen D, et al. Pitfalls in the calculation of 24-urine test results in patients with monoclonal gammopathies: serum free light chain assays provide a more accurate assessment in this setting. Hematology meeting reports 2008; 2: B8a
  168. Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008; 22: 1933 – 7 18596742
  169. Snyder MR, Clark R, Bryant SC, Katzmann JA. Quantification of urinary light chains. Clin Chem 2008; 54: 1744 – 6 PMID: 18824580
  170. Sobas M, Perez L, de Carvalho N, Encinas MP. Serum immunoglobulin free light chains for monitoring patients with oligosecretory myeloma. Hematology meeting reports 2008; 2: D30a
  171. Špička I, Mecl J, Benáková H, Nohejlová A, Straub J, Novotová E, Zima T. Comparing the detection of monoclonal protein by means of presently available biochemocal methods Klin Biochem Metab 2008; 16: 89 – 92
  172. Tang G, Snyder M, Rao LV. Assessment of serum free light chain (FLC) assays with immunofixation electrohphoresis (IFE) and bone marrow (BM) immunophenotyping in the diagnosis of plasma cell disorders. Clin Chem 2008; 54: A96a
  173. Tate J, Bazeley S, Sykes S, Mollee P. Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases: analytical and clinical correlations. Annals Clin Biochem 2008; 45: Th40a
  174. Tate JR, Bazeley S, Sykes S, Mollee P. Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - analytical and clinical correlations. Clin Chem 2008; 54: C75a
  175. Thio M, Blokhuis BR, Nijkamp FP, Redegeld FA. Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseases. Trends Pharmacol Sci 2008; 29: 170 – 4 PMID: 18353446
  176. Tichý M, Vávrová J, Friedecký B, Maisnar V. Methods for detection of free immunoglobulin light chains Klin Biochem Metab 2008; 16: 93 – 6
  177. Trieu Y, Xu W, Anglin P, Chen C, Kukreti V, Trudel S, Reece DE. Evaluation of serum free light chains and outcome in multiple myeloma patients with an intact monoclonal immunoglobulin treated with autologous stem cell transplantation. Blood 2008; 112: 3323a
  178. van Gameren II, Bijzet J, Limburg PC, Vellenga E, Van Rijswijk MH, Hazenberg BP. Diagnostic performance of measuring free light chains in fat tissue of patients with AL amyloidosis Presented at American College of Rheumatology Annual Scientific Meeting 2008: 831a
  179. Van Hoeven KH, McBride L, Lendvai N, Gonsky J, Berges T, Siegel DS. Serum free light chain testing is a more sensitive baseline marker than urine protein electrophoresis among patients undergoing primary autologous stem cell transplantation in multiple myeloma. Hematology meeting reports 2008; 2: B9a
  180. Van Hoeven KH, Wells J, Abadie A. Serum protein electrophoresis (SPEP) and serum free light chain assays: A more sensitivie approach that SPEP and urine protein electrophoresis (UPEP) for the diagnosis of monoclonal gammopathy. Renal Association Annual Congress 2008: SA-PO2501a
  181. Van Rhee F, Crowley J, Barlogie B. Response: Top tertile SFLC reduction indeed is an independent feature of myeloma aggressiveness. Blood 2008; 111: 2491
  182. Vavrova J, Friedecky B, Tichy M, Holeckova M, Maisnar V, Hajek R. The evaluation of light chains using ELISA method. Blood 2008; 112: 5147a
  183. Vávrová J, Friedecký B, Tichý M, Holečková M, Maisnar V, Hájek R. The determination of free light chains by immunoturbidimetry and ELISA Klin Biochem Metab 2008; 16: 97 – 101
  184. Vermeersch P, Marien G, Bossuyt X. More studies are needed to assess the performance of serum free light chain measurement for the diagnosis of B-cell disorders in routine clinical practice. Br J Haematol 2008; 143: 143 – 5 PMID: 18671704
  185. Vermeersch P, Van Hoovels L, Delforge M, Marien G, Bossuyt X. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder. Br J Haematol 2008; 143: 496 – 502 PMID: 18729849
  186. Vescio R. Advances in the diagnosis of multiple myeloma. Clin Adv Hematol Oncol 2008; 6: 299 – 300 PMID: 18496497
  187. Vickrey E. Multiple myeloma: vague symptoms can challenge diagnostic skills. JAAPA 2008; 21: 19 – 22 PMID: 19105542
  188. Vickrey E, Allen S, Krishnamurthy J, Singh V, Mehta J, Singhal S. The utility of serum free light chain measurement in myeloma patients with oligoclonal bands on serum or urine Immunofixation. Blood 2008; 112: 5121a
  189. Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives in treatment of AL amyloidosis. Br J Haematol 2008; 140: 365 – 77 PMID: 18162121
  190. Wechalekar AD, Lachmann HJ, Goodman HJ, Bradwell A, Hawkins PN, Gillmore JD. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 2008; 112: 4009 – 16 PMID: 18708629
  191. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93: 295 – 8 PMID: 18245653
  192. Wells JM, van Hoeven KH, Abadie JM. Serum free light chains assays in clinical practice: Impact of impaired renal function on interpretation. Clin Chem 2008; 54: C91a
  193. Went R, Chan-Lam D, Thornhill M. Isolated tongue amyloid in a patient with multiple myeloma. Br J Haematol 2008; 143: 606 PMID: 18710391
  194. White DA, Rose S, Galsinh S, Perry A, Parker A, Smith A. Comparison of normal and multiple myeloma samples measured by an ELISA free light chain assay (Biovendor) and the Binding Site Ltd nephelometric Freelite assay. Hematology meeting reports 2008; 2: B15a
  195. Willenbacher E, Gastl G, Nachbaur D, Clausen J, Willenbacher W. Free light chain analysis: Is it useful to monitor patients undergoing hematological stem cell therapy for multiple myeloma? An analysis of 'real life' data. Hematology meeting reports 2008; 2: D27a
  196. Willenbacher E, Gastl G, Nachbaur D, Willenbacher W. Free light chain analysis: Is it useful to monitor patients undergoing haematological stem cell therapy for multiple myeloma? An analysis of "real life" data. Bone Marrow Transplant 2008; 41: P674a
  197. Wood P, McElroy Y, Stone MJ. Comparison of serum immunofixation electrophoresis and free light chain assays in detection of monoclonal gammopathies. Hematology meeting reports 2008; 2: B10a
  198. Wurster U. Cerebrospinal fluid analysis in multiple sclerosis and neuroborreliosis: free light chains compared with oligoclonal bands and IgG, IgA, IgM synthesis. Ann Clin Biochem 2008; 45: T9a
  199. Yoshida T, Matsuda M, Katoh N, Tazawa K, Shimojima Y, Gono T, et al. Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis. Intern Med 2008;47:1783-90 PMID: 18854629

2009

  1. Abadie JM, van Hoeven KH, Wells JM. Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis? Am J Clin Pathol 2009; 131: 166 – 71 PMID: 19141376
  2. Airoldi A, Quaglia M, Fenoglio R, Lazzarich E, Crespi I, Bellomo G, et al. Pitfalls in nephrology: Renal threshold for serum free light chains required to produce Bence-Jones proteinuria. Presented at World Congress Nephrology, Milan 2009: M182a
  3. Almeshhedani M, Salamat A, Al-Ismail S. Evaluating the potential use of risk categorisation in the management of MGUS. Haematologica 2009; 94: 969a
  4. Arrobas Velilla T, Bermudo Guitarte C, Duro Millan R, Santos Rey K, Sanchez Margalet V, Arjona Rueda I, Goberna Ortiz R. Use of serum free light chain concentrations as an early response marker in multiple myeloma (MM). Clin Chem 2009: C69a
  5. Arneth B, Birklein F. High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid. Acta Neurol Scand 2009; 119: 39 – 44 PMID: 18573131
  6. Audard V, Matignon M, Weiss L, Remy P, Pardon A, Haioun C, et al. Successful long-term outcome of the first combined heart and kidney transplant in a patient with systemic AL amyloidosis. Am J Transplant 2009; 9: 236 – 40 PMID: 19067666
  7. Bakker AJ, Bierma-Ram A, der Werf CE, Strijdhaftig ML, van Zanden JJ. Quantitation of Serum Free Light Chains. Clin Chem 2009 PMID: 19498053
  8. Basnayake K, Cheung CK, Hutchison C, Cook M, Rylance P, Stoves J, et al. Differential evolution of renal scrarring in cast nephropathy despite early reductions in seum free light chains. Presented at NKF Spring Clinical Meeting 2009
  9. Basnayake K, Ghonemy T, Hutchison C, Bradwell AR, Cockwell P. Immunoglobulin free light chains in situ in patients with chronic kidney disease. Presented at NKF Spring Clinical Meeting 2009
  10. Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009 PMID: 19673884
  11. Blade J, Rosinol L, Cibeira MT. Are all myelomas preceded by MGUS? Blood 2009; 113: 5370 PMID: 19478048
  12. Boer K, Deufel T. Quantitation of serum free light chains does not compensate for serum immunofixation only when screening for monoclonal gammopathies. Clin Chem Lab Med 2009;47:1109-15 PMID: 19728853
  13. Bradwell AR, Harding SJ, Fourrier NJ, Wallis GL, Drayson MT, Carr-Smith HD, Mead GP. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem 2009;55:1646-55 PMID: 19617289
  14. Chee CE, Kumar S, Larson DR, Kyle RA, Dispenzieri A, Gertz MA, et al. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood 2009 PMID: 19641191
  15. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 2009; 94: 380 – 6 PMID: 19211640
  16. Cohen G, Horl WH. Free immunoglobulin light chains as a risk factor in renal and extrarenal complications. Semin Dial 2009;22:369-72 PMID: 19708983
  17. Comenzo RL. How I treat amyloidosis. Blood 2009
  18. Cook M, Hutchison C, Basu S, Cockwell P, Bradwell AR. FLC removal HD improves outcome in Myeloma kidney. Clin Lymphoma Myeloma 2009; 9: A069a
  19. De Filippi R, Iaccarino G, Frigeri F, Di Francia R, Crisci S, Capobianco G, et al. Elevation of clonal serum free light chains in patients with HIV-negative primary effusion lymphoma (PEL) and PEL-like lymphoma. Br J Haematol 2009 PMID: 19681885
  20. De Filippi R, Laccarino G, Frigeri F, Russo F, Di Francia R, Distinyo M, et al. Serum free-immunoglobulin light chains testing is frequently abnormal in patients with B-cell Non-Hodgkin and Hodgkin Lymphoma and may change in value for prognosis and therapeutic monitoring. Clin Lymphoma Myeloma 2009; 9: A412a
  21. Decaux O, Briand PY, Guenet L, Sebillot M, Jego P, Grosbois B. Frequency of abnormal serum free light chain ratio in a French cohort of patients with MGUS. Clin Lymphoma Myeloma 2009; 9: B373a
  22. Delbes S, Bridoux F, Tennent G, Valleix S, Touchard G, Goujon JM. Predominant renal hereditary amyloidosis caused by a novel apolipoproteine (Apo) A1 variant. Presented at World Congress Nephrology, Milan 2009: Su046a
  23. Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma 2009;9:302-6 PMID: 19717380
  24. Diamantidis MD, Ioannidou-Papagiannaki E, Ntaios G. Novel extended reference range for serum kappa/lambda free light chain ratio in diagnosing monoclonal gammopathies in renal insufficient patients. Clin Biochem 2009; 42: 1202 – 3 PMID: 19375413
  25. Dimopoulos MA, Kyle RA, Jagannath S. Guidelines for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3. Online publication 2009
  26. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215 – 24 PMID: 19020545
  27. Drayson M, Cobbold M, Goodall M, Wang Y, Birtwhistle J, Jefferis R. Monoclonal antibodies that provide a reliable new assay for serum immunoglobulin FLC in Myeloma. Clin Lymphoma Myeloma 2009; 9: A355a
  28. Drayson MT, Behrens J, Cohen DR, Iggo N, Gregory WM, Bell SE, et al. Serum FLC levels can be reduced rapidly; lower levels are associated with renal recovery. Clin Lymphoma Myeloma 2009;9: A351a
  29. Drayson MT, Morgan GJ, Jackson GH, Davies FE, Owen RG, Ross FM, et al. Prospective study of serum FLC and other M-protein assays: when and how to measure response? Clin Lymphoma Myeloma 2009; 9: A346a
  30. Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, et al. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Jpn J Clin Oncol 2009; 39: 449 – 55 PMID: 19487425
  31. Esperanza E, Sanchez-Navarro MR, Caffarena C, Mora-Vallellano J, Zafra-Ceres M, Samaniego-Sanchez C. Algorithm for monoclonal gammopathies diagnosis. To prospective study of incidence from our population. Haematologica 2009; 94: 1611a
  32. Fernández de Larrea C, Cibeira MT, Elena M, Rosiñol L, Rovira M, Arostegui JJ, et al. Abnormal serum free-light chain ratio in patients with Multiple Myeloma in long-lasting complete remission: strong association with oligoclonal bands. Haematologica 2009; 94: 375a
  33. Fulton RB, Fernando SL. Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy. Ann Clin Biochem 2009;46:407-12 PMID: 19641008
  34. Gera M, Jeevan R, Dhar S, Shaheen M, Phillips CL. Idiopathic light chain deposition disease (LCDD) with light chain cast nephropathy (LCCN) treated with Bortezomib. A case report and review of treatment/prognostic factors. Presented at NKF Spring Clinical Meeting 2009
  35. Giraldo P, Recasens V, Rubio-Escuin R, Rubio-Martinez A, Pascual T, Giraldo P. Predictive value of serum free light chains ratio in relapsed of multiple myeloma after autologous transplant Haematologica 2009; 94: 1615a
  36. Harding SJ, Mead GP, Bradwell AR, Berard AM. Serum free light chain immunoassay as an adjunct to serum protein electrophoresis and immunofixation electrophoresis in the detection of multiple myeloma and other B-cell malignancies. Clin Chem Lab Med 2009; 47: 302 - 4 PMID: 19676141
  37. Harding SJ, Sharp K, Steiner A, Russ G, Blackmore S, Mead G, et al. Quantification of polymerising serum free light chains. Clin Lymphoma Myeloma 2009; 9: B101a
  38. Harousseau JL, Dreyling M. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20: 97 – 9 PMID: 19454476
  39. Hata H, Nishi K, Oshihara W, Arai J, Shimizu K, Kawakita T, et al. Letter to the Editor: Adsorption of Bence–Jones protein to polymethylmethacrylate membrane in primary amyloidosis. Amyloid 2009; 16: 108 – 10
  40. Heher EC, Spitzer TR, Goes NB. Light chains: heavy burden in kidney transplantation. Transplantation 2009; 87: 947 – 52 PMID: 19352111
  41. Higgins C. Myeloma and monoclonal gammopathy of undetermined significance. Biomed Sci 2009;September
  42. Hobbs J, Legg A, Giroux M. Clinical applications of serum free light chain analysis. Biomed Sci 2009; April: 285 – 6
  43. Hughes M, Soutar R, Lucraft H, Owen R, Bird J. Guidelines on the diagnosis and management of solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas: 2009 update. Online publication 2009
  44. Hutchison C, Meryon I, Hewins P, Drayson M, Cockwell P. High cut-off haemodialysis improves pro-inflammatory status when used in a chronic haemodialysis schedule: an open-label crossover study. Renal Association Annual Congress 2009: P104a
  45. Hutchison C, Pinney J, Jain P, Ghonemy T, Cockwell P. Incidence of significant haemorrhagic complications of renal biopsies in patients with and without monoclonal gammopathies. Renal Association Annual Congress 2009: P123a
  46. Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009; 4: 745 - 54 PMID: 19339414
  47. Kaplan B, Ramirez-Alvarado M, Sikkink L, Golderman S, Dispenzieri A, Livneh A, Gallo G. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. Br J Haematol 2009; 144: 705 – 15 PMID: 19076171
  48. Katodritou E, Gastari V, Verrou E, Hadjiaggelidou C, Varthaliti M, Georgiadou S, et al. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? Leuk Res 2009; 33: 1137 – 40 PMID: 19250676
  49. Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, et al. Screening Panels for Detection of Monoclonal Gammopathies. Clin Chem 2009 PMID: 19520758
  50. Kleeberg L, Morgera S, Jakob C, Hocher B, Schneider M, Peters H, et al. Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy. Eur J Med Res 2009; 14: 47 – 54 PMID: 19258212
  51. Kühnemund A, Liebisch P, Bauchmuller K, Zur Hausen A, Veelken H, Wasch R, Engelhardt M. 'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol 2009; 135: 477 – 84 PMID: 18802723
  52. Kumar R, Gupta D, Raina V, Sharma A, Kumar L, Irshad M, et al. sFLC in healthy Indian subjects and myeloma patients. Clin Lymphoma Myeloma 2009; 9: A576a
  53. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3 – 9 PMID: 18971951
  54. Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol 2009; 46: 110 – 7 PMID: 19389494
  55. Landgren O, Goedert J, Rabkin C, Wilson W, Dunleavy K, Kyle R, et al. Risk of AIDS non-Hodgkin’s lymphoma is strongly predicted by elevated levels of circulating immunoglobulin-free light chains. Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal 2009: 29a
  56. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412 - 7 PMID: 19179464
  57. Landgren O, Kyle RA, Rajkumar V. Response: Multiple myeloma is universally preceded by a prolonged premalignant stage: novel clinical insights and future directions. Blood 2009; 114: 2356 - 7
  58. Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 2009 PMID: 19587704
  59. LeSourd S, Sweat K, Johnston M, Marshall J, Bornhorst J. Method comparison of quantitative serum free light chain immunoassays performed on nephelometric versus turbidimetric platforms. Clin Chem 2009: D160a
  60. Legg A, Hobbs JA, Mead GP, Bradwell AR, Davern S, Solomon A. Monoclonal vs polyclonal free light chain assays. Am J Clin Pathol 2009; 131: 901 – 2 PMID: 19461100
  61. Madan S, Greipp PR. The incidental monoclonal protein: Current approach to management of monoclonal gammopathy of undetermined significance (MGUS). Blood Rev 2009 PMID: 19699016
  62. Maisnar V, Vavrova J, Friedecky B, Tichy M, Radocha J, Hajek R. The evaluation of free light chains using the ELISA method. Clin Lymphoma Myeloma 2009; 9: B391a
  63. Marshall G, Tate J, Mollee P. Borderline high serum free light chain kappa/lambda ratios are seen not only in dialysis patients but also in non-dialysis-dependent renal impairment and inflammatory states. Am J Clin Pathol 2009; 132: 309 PMID: 19605825
  64. Matsue K, Fujiwara H, Iwama KI, Kimura SI, Yamakura M, Takeuchi M. Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years. Ann Hematol 2009 PMID: 19693498
  65. McCudden CR, Voorhees PM, Hammett-Stabler CA. A case of hook effect in the serum free light chain assay using the Olympus AU400e. Clin Biochem 2009; 42: 121 – 4 PMID: 18996106
  66. Mead GP, Drayson MT. Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients. Blood 2009; 114: 1717 PMID: 19696211
  67. Mead GP, Stubbs PD, Goodman HJB, Hawkins PN. Serum and urine light chains in AL amyloidosis. Clin Lymphoma Myeloma 2009; 9: B153a
  68. Meng QH, Chibbar R, Pearson D, Kappel J, Krahn J. Heat-insoluble cryoglobulin in a patient with essential type II cryoglobulinemia and cryoglobulin-occlusive membranoproliferative glomerulonephritis: Case report and literature review. Clin Chim Acta 2009 PMID: 19463798
  69. Merlini G. Serum-free light chain analysis: works in progress. Clin Chem Lab Med 2009; 47: 1021 - 2 PMID: 19728842
  70. Nair B, Waheed S, Szymonifka J, Shaughnessy JD, Jr., Crowley J, Barlogie B. Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols. Br J Haematol 2009; 145: 134 – 7 PMID: 19120351
  71. Palladini G, Merlini G. Current treatment of AL amyloidosis. Haematologica 2009; 94: 1044 - 8 PMID: 19644136
  72. Palladini G, Russo P, Bosoni T, Sarais G, Lavatelli F, Foli A, et al. AL Amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. Clin Lymphoma Myeloma 2009; 9: 80 – 3 PMID: 19362981
  73. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009; 55: 499 – 504 PMID: 19131635
  74. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 2009; 23: 449 – 56 PMID: 19005483
  75. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009 PMID: 19494840
  76. Pasquali S, Mancini E, Morabito S, Perego A, Besso L, Frascà G, et al. A kinetic study on free light chains (FLC) removal by means of a high cut-off (HCO) membrane: Comparison between hemodialysis (HD) and hemodiafiltration (HDF). Presented at World Congress Nephrology, Milan 2009: M449a
  77. Patriarca F, Petrucci MT, Bringhen S, Baldini L, Caravita T, Corradini P, et al. Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. Eur J Haematol 2009; 82: 93 – 105 PMID: 19018865
  78. Petchey M, Fletcher M, Hobbs J. Screening for monoclonal gammopathies in patients with unexplained renal failure. Renal Association Annual Congress 2009: P126a
  79. Piehler AP, Urdal P. In Reply. Clin Chem 2009 PMID: 19520757
  80. Poshusta TL, Sikkink LA, Leung N, Clark RJ, Dispenzieri A, Ramirez-Alvarado M. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. PLoS ONE 2009; 4: e5169 PMID: 19365555
  81. Pratt G, Harding S, Holder R, Fegan C, Pepper C, Oscier D, et al. Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. Br J Haematol 2009; 144: 217 – 22 PMID: 19016722
  82. Pratt G, Richter A, Huisson A, Drayson M, Harding S. Multiple Myeloma with monoclonal free IgG3 heavy chains and free kappa light chains. Clin Lymphoma Myeloma 2009; 9: A177a
  83. Radovic V. Recommendations for use of FLC tests in monoclonal gammopathies. Haematologica 2009; 94: 1628a
  84. Radovic VR. Advantage of serum measurments free light chain in plasma cells disorders. Haematologica 2009; 94: 1635a
  85. Rajkumar SV. Multiple myeloma. Curr Probl Cancer 2009; 33: 7 – 64 PMID: 19254626
  86. Rajkumar SV. Prevention of Progression in Monoclonal Gammopathy of Undetermined Significance. Clin Cancer Res 2009 PMID: 19737944
  87. Rajkumar SV, San Miguel J, Harousseau JL. Guidelines for the Uniform Reporting of Clinical Trials: Report of the International Myeloma Workshop Consensus Panel I. Online publication 2009
  88. Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009; 114: 1489 - 97 PMID: 19498019
  89. Rogoski RR. Serum free light chain assays: detecting plasma cell disorders. MLO Med Lab Obs 2009;41:10, 2-6; quiz 20-1 PMID: 19685691
  90. Sanchez-Jimenez F, Bermudo-Guitarte C, Cisneros-Barrera G, Goberna R. Demonstration of serum monoclonal immunoglobulin light chain in a case of non-secretory multiple myeloma. Presented at 2nd European Congress of Immunology 2009
  91. Robson EJD, Taylor J, Beardsmore C, Basu S, Mead G, Lovatt T. Utility of serum free light chain analysis when screening for lymphoproliferative disorders. Lab Med 2009; 40: 325 – 9
  92. Sauter A, Weisel K, Horger M. Imaging findings in relapsing multiple myeloma. Br J Haematol 2009 PMID: 19344424
  93. Schaar CG, le Cessie S, Snijder S, Franck PF, Wijermans PW, Ong C, Kluin-Nelemans H. Long-term follow-up of a population based cohort with monoclonal proteinaemia. Br J Haematol 2009; 144: 176 – 84 PMID: 19036113
  94. Sengul S, Li M, Batuman V. Myeloma kidney: toward its prevention – with new insights from in vitro and in vivo models of renal injury. J Nephrol 2009; 22: 17 – 28 PMID: 19229815
  95. Shaheen SP, Levinson SS. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect. Clin Chim Acta 2009
  96. Siegel DS, Bilotti E, Van Hoeven K. Serum free light chain analysis for diagnosis, monitoring, and prognosis of monoclonal gammopathies. Lab Med 2009; 40: 363 – 6
  97. Siegel DS, McBride L, Bilotti E, Lendvai N, Gonsky J, Berges T, et al. Inaccuracies in 24-hour urine testing for monoclonal gammopathies. Lab Med 2009; 40: 341 – 4
  98. Singhal S, Vickrey E, Krishnamurthy J, Singh V, Allen S, Mehta J. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood 2009; 114: 38 – 9 PMID: 19411633
  99. Stankowski-Drengler TJ, Lockington KS, Snyder MR, Dispenzieri A, Lust JA, Kyle RA, Katzmann JA. Reflex testing for the diagnosis of monoclonal gammopathies. Clin Chem 2009: C85a
  100. Sthaneshwar P, Nadarajan V, Maniam JA, Nordin N, Gin Gin G. Serum free light chains: diagnostic and prognostic value in multiple myeloma. Clin Chem Lab Med 2009; 47: 1101 - 7 PMID: 19728852
  101. Tate JR, Bazeley S, Sykes S, Mollee P. Dilution anomalies in serum free light chain measurement. Clin Chem 2009: C11a
  102. Terrier B, Sene D, Saadoun D, Ghillani-Dalbin P, Thibault V, Delluc A, et al. Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Ann Rheum Dis 2009; 68: 89 – 93 PMID: 18375535
  103. Tzenou T, Vassilakopoulos TP, Kafasi N, Sachanas S, Koulieris E, Maltezas D, et al. sFLC R in LPL/WM patients at diagnosis. Clin Lymphoma Myeloma 2009; 9: A424a
  104. Uljon SN, Richardson PG, Grudzien C, Schur PH, Tanasijevic MJ, Lindeman NI. Changes in serum free light chain values do not precede changes in M-spike in a series of patients with relapsed/refractory intact immunoglobulin multiple myeloma. Clin Chem 2009: D176a
  105. Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 2009; 114: 785 - 90 PMID: 19179466
  106. van Gameren I, van Rijswijk MH, Bijzet J, Vellenga E, Hazenberg BP. Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. Haematologica 2009; 94: 1094 - 100 PMID: 19644141
  107. van Hoeven K, Wells J, Abadie J. Serum protein electrophoresis (SPEP) plus serum free light chain (sFLC) testing: A sensitive panel for diagnosis of monocloal gammopathy (MG). Presented at NKF Spring Clinical Meeting 2009
  108. van Hoeven KH, Bilotti E, McBride L, Berges T, McNeill A, Schillen D, Siegel D. Serum free light chain assays are more sensitive than urinary tests for light chain monoclonal proteins. Clin Chem 2009: C30a
  109. Watanaboonyongcharoen P, Suwannabutra S, Theerasaksilp S, Paripokee N, Na Nakorn T. The roles of serum free light chain assay on the prognosis of multiple myeloma. Clin Lymphoma Myeloma 2009; 9: A420a
  110. Wechalekar A, Hawkins PN, Wassef NJ, Gillmore ND, Lachmann HJ, Morris J, et al. Monoclonal protein detection in AL amyloidosis revisited: Analysis of 642 patients. Clin Lymphoma Myeloma 2009; 9: A300a
  111. Wechalekar AD, Nassef N, Lachmann H, Sattianayagam P, Gibbs SDJ, Gillmore J, Hawkins PN. High early mortality and poor outcomes for patients with AL amyloidosis presenting with high serum free light chains - A new risk stratification model. Haematologica 2009; 94: 544a
  112. Weisel KC, Hänel M, Niederwieser D, Naumann R, Kröger N, Engelhardt M, et al. Speed of response with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma: First results of the MM-019 German compassionate use protocol. Haematologica 2009; 94: 397a
  113. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418 – 22 PMID: 19234139
  114. Wians FH. Use of Excel spreadsheets to create interpretive reports for laboratory tests requiring complex calculations. Lab Med 2009; 40: 5 – 12
  115. Willenbacher E, Nachbaur D, Gastl G, Gasser S. Free light chain (by rFLC) monitoring reveals early relapse after HSCT. Clin Lymphoma Myeloma 2009; 9: A326a
  116. Yegin ZA, Yagci M, Özkurt ZN, Kursunoglu N, Aki SZ. Abnormal serum free light chain ratio as a predictor of adverse outcome in chronic lymphocytic leukemia: Has the time come for a simple prognostic marker? Haematologica 2009; 94: 929a
Chapter 30 Back to Contents Page Chapter 32
Retrieved from "http://www.wikilite.com/wiki/index.php/Serum_free_light_chain_publications"